2018

SFCR

ASR Basis

Ziektekostenverzekeringen

N.V.
2018

SFCR
ASR Basis
Ziektekostenverzekeringen N.V.
## Contents

<table>
<thead>
<tr>
<th>Introduction</th>
<th>7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Summary</td>
<td>8</td>
</tr>
<tr>
<td>A Business and performance</td>
<td>8</td>
</tr>
<tr>
<td>B System of governance</td>
<td>8</td>
</tr>
<tr>
<td>C Risk profile</td>
<td>8</td>
</tr>
<tr>
<td>D Valuation for Solvency purposes</td>
<td>9</td>
</tr>
<tr>
<td>E Capital management</td>
<td>10</td>
</tr>
<tr>
<td>A Business and performance</td>
<td>11</td>
</tr>
<tr>
<td>A.1 Business</td>
<td>11</td>
</tr>
<tr>
<td>A.1.1 Profile</td>
<td>11</td>
</tr>
<tr>
<td>A.1.2 General information</td>
<td>16</td>
</tr>
<tr>
<td>A.2 Underwriting performance</td>
<td>17</td>
</tr>
<tr>
<td>A.3 Investment performance</td>
<td>18</td>
</tr>
<tr>
<td>A.3.1 Financial assets and derivatives</td>
<td>18</td>
</tr>
<tr>
<td>A.3.2 Company statement of comprehensive income</td>
<td>19</td>
</tr>
<tr>
<td>A.3.3 Information about investments in securities</td>
<td>19</td>
</tr>
<tr>
<td>A.4 Performance of other activities</td>
<td>19</td>
</tr>
<tr>
<td>A.5 Any other information</td>
<td>19</td>
</tr>
<tr>
<td>B System of governance</td>
<td>20</td>
</tr>
<tr>
<td>B.1 General information on the system of governance</td>
<td>20</td>
</tr>
<tr>
<td>B.1.1 Corporate governance</td>
<td>20</td>
</tr>
<tr>
<td>B.1.2 Related-party transactions</td>
<td>22</td>
</tr>
<tr>
<td>B.1.3 Remuneration of Supervisory Board and Executive Board</td>
<td>22</td>
</tr>
<tr>
<td>B.2 Fit and proper requirements</td>
<td>25</td>
</tr>
<tr>
<td>B.3 Risk management system including the Own Risk and Solvency Assessment Risk Management System</td>
<td>25</td>
</tr>
<tr>
<td>B.3.1 Risk Management Framework</td>
<td>25</td>
</tr>
<tr>
<td>B.3.2 a.s.r.'s risk categories</td>
<td>33</td>
</tr>
<tr>
<td>B.4 Internal control system</td>
<td>34</td>
</tr>
<tr>
<td>B.4.1 Strategic and operational risk management</td>
<td>34</td>
</tr>
<tr>
<td>B.4.2 Compliance function</td>
<td>36</td>
</tr>
<tr>
<td>B.5 Internal audit function</td>
<td>36</td>
</tr>
<tr>
<td>B.6 Actuarial function</td>
<td>37</td>
</tr>
<tr>
<td>B.7 Outsourcing</td>
<td>38</td>
</tr>
<tr>
<td>B.8 Any other information</td>
<td>38</td>
</tr>
<tr>
<td>C Risk profile</td>
<td>39</td>
</tr>
<tr>
<td>C.1 Insurance risk</td>
<td>43</td>
</tr>
<tr>
<td>C.1.1 Health insurance risk</td>
<td>43</td>
</tr>
<tr>
<td>C.1.2 Managing health insurance risk</td>
<td>45</td>
</tr>
<tr>
<td>C.2 Market risk</td>
<td>45</td>
</tr>
<tr>
<td>C.2.1 Interest rate risk</td>
<td>46</td>
</tr>
<tr>
<td>C.2.2 Equity risk</td>
<td>46</td>
</tr>
<tr>
<td>C.2.3 Property risk</td>
<td>47</td>
</tr>
<tr>
<td>C.2.4 Currency risk</td>
<td>47</td>
</tr>
<tr>
<td>C.2.5 Spread risk</td>
<td>48</td>
</tr>
<tr>
<td>C.2.6 Market risk concentrations</td>
<td>49</td>
</tr>
<tr>
<td>C.3 Counterparty default risk</td>
<td>50</td>
</tr>
<tr>
<td>C.3.1 Mortgages</td>
<td>50</td>
</tr>
<tr>
<td>C.3.2 Savings-linked mortgage loans</td>
<td>50</td>
</tr>
<tr>
<td>C.3.3 Derivatives</td>
<td>50</td>
</tr>
<tr>
<td>C.3.4 Reinsurance</td>
<td>51</td>
</tr>
<tr>
<td>C.3.5 Receivables</td>
<td>51</td>
</tr>
<tr>
<td>C.3.6 Cash and cash equivalents</td>
<td>51</td>
</tr>
<tr>
<td>C.4 Liquidity risk</td>
<td>52</td>
</tr>
<tr>
<td>C.5 Operational risk</td>
<td>53</td>
</tr>
<tr>
<td>C.6 Other material risks</td>
<td>53</td>
</tr>
<tr>
<td>C.7 Any other information</td>
<td>53</td>
</tr>
<tr>
<td>C.7.1 Description of off-balance sheet positions</td>
<td>53</td>
</tr>
<tr>
<td>C.7.2 Reinsurance policy and risk budgeting</td>
<td>53</td>
</tr>
<tr>
<td>C.7.3 Monitoring of new and existing products</td>
<td>53</td>
</tr>
<tr>
<td>C.7.4 Prudent person principle</td>
<td>53</td>
</tr>
<tr>
<td>D Valuation for Solvency Purposes</td>
<td>54</td>
</tr>
<tr>
<td>D.1 Assets</td>
<td>55</td>
</tr>
<tr>
<td>D.1.1 Fair value measurement</td>
<td>55</td>
</tr>
<tr>
<td>D.1.2 Assets per asset category</td>
<td>56</td>
</tr>
<tr>
<td>D.2 Technical provisions</td>
<td>57</td>
</tr>
<tr>
<td>D.2.1 Introduction</td>
<td>57</td>
</tr>
<tr>
<td>D.2.2 Technical provisions methods</td>
<td>57</td>
</tr>
<tr>
<td>D.2.3 Level of uncertainty</td>
<td>59</td>
</tr>
<tr>
<td>D.2.4 Reinsurance and special purpose vehicles (SPVs)</td>
<td>59</td>
</tr>
<tr>
<td>D.2.5 Technical provisions</td>
<td>59</td>
</tr>
<tr>
<td>D.2.6 Reconciliation between IFRS and Solvency II</td>
<td>59</td>
</tr>
<tr>
<td>D.3 Other liabilities</td>
<td>59</td>
</tr>
<tr>
<td>D.3.1 Valuation of other liabilities</td>
<td>59</td>
</tr>
<tr>
<td>D.3.2 Reconciliation from Solvency II equity to EOF</td>
<td>60</td>
</tr>
<tr>
<td>D.4 Alternative methods for valuation</td>
<td>60</td>
</tr>
<tr>
<td>D.5 Any other information</td>
<td>60</td>
</tr>
<tr>
<td>E</td>
<td>Capital management</td>
</tr>
<tr>
<td>-----</td>
<td>--------------------</td>
</tr>
<tr>
<td>E.1</td>
<td>Own funds</td>
</tr>
<tr>
<td>E.1.1</td>
<td>Capital management objectives</td>
</tr>
<tr>
<td>E.1.2</td>
<td>Tiering own funds</td>
</tr>
<tr>
<td>E.1.3</td>
<td>Own funds versus MCR</td>
</tr>
<tr>
<td>E.1.4</td>
<td>Description of grandfathering</td>
</tr>
<tr>
<td>E.2</td>
<td>Solvency Capital Requirement</td>
</tr>
<tr>
<td>E.3</td>
<td>Use of standard equity risk sub-module in calculation of Solvency Capital Requirement</td>
</tr>
<tr>
<td>E.4</td>
<td>Differences between Standard Formula and internal models</td>
</tr>
<tr>
<td>E.5</td>
<td>Non-compliance with the Minimum Capital Requirement and non-compliance with the Solvency Capital Requirement</td>
</tr>
<tr>
<td>E.6</td>
<td>Any other information</td>
</tr>
<tr>
<td>E.6.1</td>
<td>Dividend policy and capital management actions</td>
</tr>
</tbody>
</table>
Introduction

The structure of the Solvency and Financial Condition Report (SFCR) has been prepared as described in annex XX of the Solvency II Directive Delegated Regulation. The subjects addressed are based on article 51 to 56 of the Solvency II Directive and act 292 up to and including 298 and act 359 of the Delegated Regulation. Furthermore, the figures presented in this report are in line with the supervisor’s reported Quantitative Reporting Templates.

All amounts in this report, including the amounts quoted in the tables, are presented in thousands of euros (€ thousand), being the functional currency of ASR Basis Ziektekostenverzekeringen N.V., unless otherwise stated.
The 2018 Solvency and Financial Condition Report provides ASR Basis Ziektekostenverzekeringen N.V.’s stakeholders insight in:

A Business and performance

The Solvency II ratio stood at 140% as at 31 December 2018, based on the standard formula as a result of € 128,801 thousand Eligible Own Funds and € 92,071 thousand Solvency Capital Requirement (SCR).


Specifically, regarding ASR Basis Ziektekostenverzekeringen N.V. in 2018, no dividend or capital withdrawals have taken place.

Full details on the ASR Basis Ziektekostenverzekeringen N.V.’s business and performance are described in chapter A Business and performance (page 11).

B System of governance

This paragraph contains a description of group policy, which is applicable for the solo entity.

General

a.s.r. is a public company with limited liability listed on Euronext Amsterdam and governed by Dutch corporate law. a.s.r. has a two-tier board governance structure, consisting of an Executive Board and Supervisory Board. The Executive Board is responsible for the realisation of corporate objectives, the strategy with its associated risks and the development of the results. The Supervisory Board is responsible for advising the Executive Board and supervising the policies of the Executive Board and the general state of affairs at a.s.r. and its group entities. On 19 November 2018 a.s.r. announced that its management structure will change as of 1 February 2019. From that date the Executive Board consists of the CEO, the CFO and a new member to be appointed and in addition to the Executive Board a Business Executive Committee (BEC) will be established. The BEC will work as a unison with the Executive Board, and is co-responsible for the implementation of the business strategy.

Risk management

It is of great importance to a.s.r. that risks within all business lines are timely and adequately controlled. In order to do so, a.s.r. has implemented a Risk Management framework based on internationally recognized and accepted standards (such as COSO ERM and ISO 31000:2018 risk management principles and guidelines). Using this framework, material risks that a.s.r. is, or can be, exposed to, are identified, measured, managed, monitored and evaluated. The framework is applicable to a.s.r. group, ASR Basis Ziektekostenverzekeringen N.V. and other underlying business entities.

Control environment

In addition to risk management, a.s.r.’s Solvency II control environment consist of an internal control system, an actuarial function, a compliance function, and an internal audit function. The system of internal control includes the management of risks at different levels in the organization, both operational and strategic. Internal control at an operational level centres around identifying and managing risks within the critical processes that pose a threat to the achievement of the business line’s objectives. The actuarial function is responsible for expressing an opinion on the adequacy and reliability of reported technical provisions, reinsurance and underwriting. The mission of the compliance function is to enhance and ensure a controlled and sound business operation where impeccable, professional conduct is self-evident. The Audit Department evaluates the effectiveness of governance, risk management and internal control processes, and gives practical advice on process optimization.

Full details on the ASR Basis Ziektekostenverzekeringen N.V.’s system of governance are described in chapter B System of governance (page 20).

C Risk profile

ASR Basis Ziektekostenverzekeringen N.V. applies an integrated approach in managing risks, ensuring that our strategic goals (customer interests, financial solidity and efficiency of processes) are maintained. This integrated approach ensures that value will be created by identifying the right balance between risk and return, while ensuring that obligations towards our stakeholders are met. Risk management supports ASR Basis Ziektekostenverzekeringen N.V. in the identification, measurement and management of risks and monitors to ensure adequate and immediate actions are taken in the event of changes in ASR Basis Ziektekostenverzekeringen N.V.’s risk profile.
ASR Basis Ziektekostenverzekeringen N.V. is exposed to the following types of risks: market risk, counterparty default risk, insurance risk, strategic risk and operational risk. The risk appetite is formulated at both group and legal entity level and establishes a framework that supports an effective selection of risks.

The solvency capital requirement is build up as follows:

<table>
<thead>
<tr>
<th>Year</th>
<th>Market</th>
<th>Insurance</th>
<th>Counterparty</th>
<th>Operational</th>
<th>Diversification</th>
<th>LAC DT</th>
<th>SCR</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>70,379</td>
<td>3,561</td>
<td>-7,611</td>
<td>0</td>
<td>92,071</td>
<td></td>
<td>7,228</td>
</tr>
<tr>
<td>2017</td>
<td>68,765</td>
<td>9,242</td>
<td>-11,552</td>
<td>0</td>
<td>91,452</td>
<td></td>
<td>7,620</td>
</tr>
</tbody>
</table>

Full details on the ASR Basis Ziektekostenverzekeringen N.V.’s risk profile are described in chapter C Risk profile (page 39).

D Valuation for Solvency purposes

ASR Basis Ziektekostenverzekeringen N.V. values its Solvency II balance sheet items on a basis that reflects their economic value. Where the IFRS fair value is consistent with Solvency II requirements, ASR Basis Ziektekostenverzekeringen N.V. follows IFRS for valuing assets and liabilities other than technical provisions.

The reconciliation of IFRS equity and Excess Assets over Liabilities (Solvency II basis) can be summarized as follows:

- Derecognition of items on the Solvency II economic balance sheet which are admissible on the IFRS balance sheet, for instance goodwill, pre-paid commissions and other intangible assets;
- Revaluation differences on mainly insurance liabilities and other assets which are valued other than fair value in the IFRS balance sheet.

To reconcile from Solvency II equity to EOF, the following movements are taken into consideration:

- Subordinated liabilities: in accordance with the Delegated Regulation the subordinated liabilities are part of the EOF.

A graphical representation of the reconciliation from Solvency II equity to EOF is presented below.
Full details on the reconciliation between ASR Basis Ziektekostenverzekeringen N.V.’s economic balance sheet based on Solvency II and consolidated financial statements based on IFRS are described in chapter D Valuation for solvency purposes (page 54).

**E Capital management**

Overall capital management is administered at group level. Capital generated by operating units and future capital releases will be allocated to profitable growth of new business or repatriated to shareholders, beyond the capital that is needed to sustain commercial capital levels at management’s targets.

ASR Basis Ziektekostenverzekeringen N.V. has no partial internal model and follows the default method for the determination of the group solvency. ASR Basis Ziektekostenverzekeringen N.V. maintains an internal minimum for the Solvency II ratio. The internal minimum Solvency II ratio for ASR Basis Ziektekostenverzekeringen N.V. as formulated in the risk appetite statement is 110%.

The Solvency II ratio was 140% at 31 December 2018.

The EOF are build up as follows:

<table>
<thead>
<tr>
<th>Tier 1 capital - unrestricted</th>
<th>Tier 1 capital - restricted</th>
<th>Tier 2 capital</th>
<th>Tier 3 capital</th>
<th>Eligible own funds to meet SCR</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>118,413</td>
<td>0</td>
<td>0</td>
<td>128,801</td>
</tr>
<tr>
<td>2017</td>
<td>115,814</td>
<td>0</td>
<td>0</td>
<td>126,205</td>
</tr>
</tbody>
</table>

a.s.r. has formulated its dividend policy in line with its current strategy. a.s.r. and the underlying business entities intend to pay an annual dividend that creates sustainable long-term value for its shareholders. a.s.r. and the underlying business entities aim to operate at a solvency ratio, calculated according to the standard formula, above a management threshold level. However, for ASR Basis Ziektekostenverzekeringen N.V. this management threshold is not applicable as ASR Basis Ziektekostenverzekeringen N.V. thinks it is inappropriate to distribute dividend from the compulsory health insurance.

Full details on the capital management of ASR Basis Ziektekostenverzekeringen N.V. can be found in chapter E Capital Management (page 61).
A Business and performance

A.1 Business

A.1.1 Profile

Overview of brands

ASR Basis Ziektekostenverzekeringen N.V. provides healthcare insurance to all persons who are entitled to a health insurance under the Dutch Healthcare Insurance Act.

ASR Basis Ziektekostenverzekeringen N.V. aims to promote the health of its customers and improve healthcare. ASR Basis Ziektekostenverzekeringen N.V. focuses on client satisfaction and profitable growth of the customer base. We do this by offering attractive products, excellent service, a good price and visible and valued brands.

Core activities

The core activity of ASR Basis Ziektekostenverzekeringen N.V. is the implementation of the Dutch Healthcare Insurance Act. ASR Basis Ziektekostenverzekeringen N.V. offers basic health insurance. In addition to basic health insurance, ASR Nederland N.V. (hereinafter also referred to as a.s.r.), of which ASR Basis Ziektekostenverzekeringen N.V. is a part, also offers supplementary insurance through ASR Aanvullende Ziektekostenverzekeringen N.V. In addition, a legal entity was established on 1 January 2016 for the implementation of the Dutch Long-term Health Act (‘Wlz’). ASR Wlz-uitvoerder B.V. is a ‘Wlz’-implementer without a healthcare office. ASR Basis Ziektekostenverzekeringen N.V., ASR Aanvullende Ziektekostenverzekeringen N.V. and ASR Wlz-uitvoerder B.V. form a personal and administrative union (hereafter referred to as a.s.r. health). The number of insured persons of ASR Basis Ziektekostenverzekeringen N.V. amounted to 345,746 in 2018.

In 2018, the healthcare market was served from two labels: De Amersfoortse and Ditzo. De Amersfoortse focuses mainly on entrepreneurs (SMEs), employees and self-employed workers without employees. Distribution takes place via the intermediary channel. Ditzo focuses exclusively via the direct online channel on price-conscious customers looking for a good quality health insurance product. Both brands of ASR Basis Ziektekostenverzekeringen N.V. have free choice of health providers as an important principle. a.s.r. health focuses on operating all of its healthcare insurance policies under its own management. This provides the best opportunities to improve customer service for the existing labels. In addition to its own brands, health insurance is currently also offered through authorised agent Aevitae B.V. The contract with Aevitae has now been terminated.

Legal structure of the company

ASR Basis Ziektekostenverzekeringen N.V. is a wholly-owned subsidiary of ASR Ziektekostenverzekeringen N.V., which in turn is a wholly-owned subsidiary of ASR Nederland N.V. (a.s.r.). a.s.r. is a public limited company under Dutch law having its registered office located at Archimedeslaan 10, 3584 BA in Utrecht, the Netherlands. a.s.r. has chosen the Netherlands as ‘country of origin’ (land van herkomst) for the issued share capital and corporate bonds which are listed on Euronext Amsterdam and the Irish Stock Exchange. (Ticker: ASRNL).

Internal organisational structure and staffing

Internal organisational structure

In 2018, the organization of ASR Basis Ziektekostenverzekeringen N.V. was divided into the following segments: Operations and Information Management, Health, Customer, and Finance & Risk & Control. Operations includes Client Acceptance, Health Declarations and Receivables Management. Information Management includes the Data team, Health Project Management and the Health Service Chain. Health can be subdivided into the Medical Advice Group, Procurement and Policy & Advisory Bureau. Customer Health consists of the Contact Centre team and supporting functions. The departments of Health Control, Business Actuarial, Business Risk Management and Business Control together form Finance, Risk & Health Control.
Organizational chart
Below, the organizational chart of ASR Basis Ziektekostenverzekeringen N.V. is presented:

Organizational chart
Headcount
All employees are employed by a.s.r. The a.s.r. employees work for ASR Basis Ziektekostenverzekeringen N.V. as well as ASR Aanvullende Ziektekostenverzekeringen N.V. and ASR Wlz-uitvoerder B.V. In 2018, a.s.r. Health employed an average of 180 (2017: 167) internal employees. In addition, a flexible layer was used, mostly during November/December, when new business was acquired. Specific teams were supported by temporary external employees.

The Executive Board consists of J.D. Lansberg and J.M. Hendriks. The composition of the Executive Board remained unchanged in 2018.

The composition of the Supervisory Board of ASR Basis Ziektekostenverzekeringen N.V. in 2018 is as follows: C. van der Pol (Chairman), A.P. Aris, J.P.M. Baeten and M.H. Verwoest. The composition of the Supervisory Board remained unchanged in 2018. Michel Verwoest resigned as a member of the Supervisory Board on 1 February 2019.

Key elements of the policy pursued
In line with a.s.r.’s mission statement of ‘helping by doing’, its health strategy to help customers get better and healthier has been underpinned by the introduction of relevant products and services. ASR Basis Ziektekostenverzekeringen N.V. is also run as an ‘independent’ division within the Group, and supports other business lines and brands with opportunities for cross-selling and brand appreciation. ASR Basis Ziektekostenverzekeringen N.V. is aiming for further digitalisation and innovation.

Making an impact on personal health of customers
ASR Basis Ziektekostenverzekeringen N.V. aims to help customers improve their health whenever possible. It therefore provides information, services and products to customers that may help them improve their health. In 2018, it ran a pilot project consisting of an online platform giving customers insight into their health and supporting their efforts to improve their own health (such as through more exercise, less alcohol, better sleep patterns). Based on the lessons learned, ASR Basis Ziektekostenverzekeringen N.V. is looking to incorporate this kind of service into its daily customer servicing business.

Given that it considers the health of its customers as one of its core focus areas, ASR Basis Ziektekostenverzekeringen N.V. ended the outsourcing of health care procurement in 2017 and in 2018 brought the contracting of health care providers in-house. In this way, ASR Basis Ziektekostenverzekeringen N.V. aims to strengthen its relationship with health care providers for the benefit of its customers, while at the same time facilitating declaration processes in order to benefit customers and healthcare providers alike.

Customer satisfaction
As well as introducing products and services to help make customers more healthy, ASR Basis Ziektekostenverzekeringen N.V. strives to increase customer satisfaction by organising an efficient and client-focused customer service process. ASR Basis Ziektekostenverzekeringen N.V. puts considerable effort into streamlining and digitising the process of paying declarations, customer onboarding and other services, thereby leading to faster and more accurate payments to customers, customer satisfaction, lower operating costs and efficient processes. ASR Basis Ziektekostenverzekeringen N.V. also constantly updated the practical information it provided to its employees so that they can in turn improve the quality, accuracy and speed of information they give customers.

Market and distribution developments
Market developments
The health insurance market is a highly regulated market. The Dutch health care system distinguishes two types of insurance product: basic health insurance coverage and supplementary coverage. All Dutch residents are obliged to have basic health insurance coverage. Basic coverage is the same across all insurers, since it is a statutory requirement. The number of customers who switch care providers per calendar year has been relatively stable over the past four years at just under 7%. In 2018 the number of customers that switched amounted to 6.7%.

Insurers are obliged to accept all Dutch residents for basic coverage. A government-run system of risk equalisation makes this possible and provides insurers with compensation for excessive costs resulting from their customer base. The government is constantly seeking to improve the system of risk equalisation in order to give every insurer the same starting position.

GWP for basic coverage are increasing across the board due to rising health care costs. These expenses account for more than 96% of health insurers’ overall costs. Between 2016 and 2018, the GWP of the market as a whole rose by more than 11%¹.

Distribution developments
Intermediaries using a comparison site, or offering online health insurance via authorised agents, play a dominant role, together with online insurers, in the distribution of health insurance. This is similar to 2017.

Ditzo
Ditzo distinguishes itself in the market by not setting up traditional marketing campaigns and by pursuing its own efficient course with campaigns via social media, often focused on social themes. At product level, Ditzo meets customers’ needs by offering a good premium combined with a free choice of healthcare provider. Ditzo also adds value for its customers through its customer-focused

¹ Source: NZA Monitor Zorgverzekeringen 2018.
online concept, high service level and the ‘Pechvogelhulp’ accident insurance. Ditzo sells its insurance policies directly to its consumers, without the intervention of third parties.

**De Amersfoortse**

The De Amersfoortse label offers its propositions via the intermediary channel. The focus is on co-operation with those advisors who best suit the different customer groups. The account managers play a key role in this. Advisors of intermediaries increasingly realise that healthcare is a more important part of the advisory model, particularly in the business market, in line with the trend of sustainable employability of employees. With the De Amersfoortse brand, ASR Basis Ziektekostenverzekeringen N.V. serves the market of SME entrepreneurs, their families and their employees.

**Internal control of processes and procedures**

Adequate risk management within ASR Basis Ziektekostenverzekeringen N.V. is essential to control the quality of processes and procedures and keep improving the operational performance. This results in increased customer satisfaction reflected in, among other things, the Net Promotor Score (NPS).

Risk appetite statements are in place to manage the business within the risk profile limits. The Business Risk Committee (BRC) monitors on an ongoing basis and discusses on a quarterly basis whether non-financial risks are adequately managed. If a risk profile exceeds the appetite, the BRC agrees on actions to be taken.

Insight into the size and potential interconnectedness of risks enables ASR Basis Ziektekostenverzekeringen N.V. to accept risks that are responsible and consistent with the associated reward. Comprehensive risk management thus supports the preservation of financial robustness.

In 2018, ASR Basis Ziektekostenverzekeringen N.V. made efforts to further improve the effectiveness of its operational risk control framework by continuing the risk-based approach. The key risks and controls are annually evaluated and defined by management of ASR Basis Ziektekostenverzekeringen N.V.

The effectiveness of the most important control measures is tested periodically. The use of a Comprehensive Risk Management Framework gives ASR Basis Ziektekostenverzekeringen N.V. a grip on its overall risk profile and facilitates responsible risk management.

Additionally, ASR Basis Ziektekostenverzekeringen N.V. continued the implementation of the Governance and Risk Compliance (GRC) tool Cerrix by implementing new modules. Naturally, ASR Basis Ziektekostenverzekeringen N.V. will continue to look for opportunities to improve the management of its operational risks in 2019.

Alongside the periodic testing of key controls by means of a Comprehensive Risk Management Framework, our risk management is also supported by the performance of Strategic Risk Analysis (SRA), Own Risk and Solvency Assessments (ORSA), operational loss monitoring and project risk assessments.

New products and services and accompanying customer brochures undergo an internal ‘Product Approval and Review Process (PARP)’.

In 2018, ASR Basis Ziektekostenverzekeringen N.V. took various actions to enhance the measurement and reporting of data quality for financial reporting purposes and to mitigate the end-user computing risks. A project to address these items has started in the beginning of 2018 and is expected to be completed in the beginning of 2019.

At ASR Basis Ziektekostenverzekeringen N.V., costs of claims are monitored retrospectively for the following control domains: formal, material, medical necessity and fraud. A separate department (Zorgcontrole, or Health Control) has been set up for this purpose.

ASR Basis Ziektekostenverzekeringen N.V. adds scope and depth to the identification of risks and the execution of control measures. Currently, a project is being carried out to improve the billing chain by building more prospective formal controls into the systems and thus reduce the need for retrospective corrections. Outcomes of investigations and checks help to reduce and prevent billing of fraudulent and/or medically unnecessary claims. Ultimately, ASR Basis Ziektekostenverzekeringen N.V. is accountable to the Dutch Healthcare Authority (‘Nza’).

**Quality control**

ASR Basis Ziektekostenverzekeringen N.V. wants to be the most personal health insurer offering its customers an excellent service. The foundation for this is quality management. Quality management contains policies, guidelines and principles on how ASR Basis Ziektekostenverzekeringen N.V. wants to serve its customers. The standards laid down in the quality policy are the starting point in actively complying with the quality standards for customer-oriented insurance, continuous improvement of processes within all departments and providing training to employees.

In order to actively steer towards the objectives, they have been translated into key performance indicators (KPIs). The progress and results on these KPIs are periodically shared within ASR Basis Ziektekostenverzekeringen N.V.

ASR Basis Ziektekostenverzekeringen N.V. attaches great importance to feedback from its customers. That is why, in 2018, continuous feedback was requested by means of NPS on both customer contact (contact measurement) and the handling of complaints (process measurement).
We also measured the customer satisfaction of customers who used social media. This gave ASR Basis Ziektekostenverzekeringen N.V. an even better insight into what customers think of its information provision, services, First Time Right and the quality of its customer contact in general. The feedback was used to improve processes and train employees.

In 2018 ASR Basis Ziektekostenverzekeringen N.V. started using the Customer Effort Score (CES) to get an insight into how much effort the customers must deliver, for example when submitting an invoice. The results of this study have given us input for improvements.

The ambition in terms of service provision to customers is reflected in an increase in the NPS from +35.7 (overall score for our Customer Contact Center over 2017) to +39 over 2018.

In 2018, ASR Basis Ziektekostenverzekeringen N.V. continued the roll-out of the new customer contact strategy. This is aimed at enabling customers to contact us efficiently and effectively in the way and at the moment that suits them best. To this end, additional research was carried out by means of a customer panel and an extensive data analysis was carried out that gives us a good insight of how customers use the various channels.

As a result, we have put a new call-me-back application into use. In addition, we now offer customers the most suitable way to information that suits their request. In 2018 we saw an increase in the number of complaints in comparison with 2017. The number of complaints has increased from 1,150 in 2017 to 1,456 in 2018. The two main reasons for this increase are that in the beginning of the year we experienced a substantial delay in handing out the health insurance card. Excluding this source of complaints, the number of complaints declined. A recurring theme in complaints is the excess customers have to pay. Excess pay is mandatory and applies to all health insurance policies. Still, it remains a difficult topic for people to understand and is often a source of questions.

In 2018 we started with the mapping of the total customer journey. This will give us further insights about when and how customers contact us, how they appreciate this and where we can improve our processes.

In 2018 we have carried out a major project to improve the intelligibility and content on our website.

ASR Basis Ziektekostenverzekeringen N.V. conducts customer satisfaction surveys on an annual basis. The results and the resulting points for improvement were shared with our customers via the website.

**Finance**

Overall capital management is administered at Group level. ASR Basis Ziektekostenverzekeringen N.V. is capitalised separately. Excess capital over management’s targets and not allocated to profitable growth of new business, can be used to repay earlier capital investments to the extent local regulations allow and within the internal risk appetite statement. For ASR Basis Ziektekostenverzekeringen NV no upstreaming of capital to the Group level is currently foreseen. All capital present is used for strengthening of the capital positioning, investments or to maintain a socially responsible pricing level.
A.1.2 General information

The Solvency and Financial Condition Report is presented in thousands of euros (€), being the functional currency of ASR Basis Ziektekostenverzekeringen N.V. All amounts quoted in the tables contained in the SFCR are in thousands of euros, unless otherwise indicated.

The SFCR has been prepared by and is the sole responsibility of the Company's management. Selected Own Funds and SCR information are also reported in a.s.r. financial statements. EY has examined the 2018 financial statements and issued a report thereon.

Name and contact details of the supervisory authority

Name: De Nederlandsche Bank
Visiting address: Westeinde 1, 1017 ZN Amsterdam
Phone number (general): +31 800 020 1068
Phone number (business purposes): +31 20 524 9111
Email: info@dnb.nl

Name and contact details of the external auditor

Name: EY
Visiting address: Cross Towers, Antonio Vivaldistraat 150, 1083 HP Amsterdam
Phone number: +31 88 407 1000
A.2 Underwriting performance

Key figures

- The net result amounted to € -1.0 million (2017: € -2.1 million);
- Gross written premiums increased to € 620.7 million (2017: € 588.9 million);
- Operating costs decreased by 2.3% to € 19.8 million (2017: € 20.2 million);
- Combined ratio 100.1% (2017: 100.9%).

Key figures ASR Basis Ziektekostenverzekeringen N.V. separate

<table>
<thead>
<tr>
<th>(in € million, unless stated otherwise)</th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gross premiums written</td>
<td>620,722</td>
<td>588,889</td>
</tr>
<tr>
<td>Operating expenses</td>
<td>-19,774</td>
<td>-20,246</td>
</tr>
<tr>
<td>Profit (loss) before tax</td>
<td>-1,276</td>
<td>-2,839</td>
</tr>
<tr>
<td>Income tax (expense) / gain</td>
<td>319</td>
<td>710</td>
</tr>
<tr>
<td>Profit (loss) for the year</td>
<td>-957</td>
<td>-2,129</td>
</tr>
<tr>
<td>New business</td>
<td>37,608</td>
<td>58,063</td>
</tr>
<tr>
<td>Combined ratio</td>
<td>100.1%</td>
<td>100.9%</td>
</tr>
<tr>
<td>- Claims ratio</td>
<td>96.3%</td>
<td>96.9%</td>
</tr>
<tr>
<td>- Commission ratio</td>
<td>0.7%</td>
<td>0.8%</td>
</tr>
<tr>
<td>- Expense ratio</td>
<td>3.2%</td>
<td>3.2%</td>
</tr>
</tbody>
</table>

Gross new business

More than 41,000 new insured persons opted for one of the two labels of ASR Basis Ziektekostenverzekeringen N.V. in 2018 (2017: more than 65,000). Yet, Ditzo achieved a netto decline in the number of insured persons in 2018. The decrease in the number of insured persons in 2018 at ASR Basis Ziektekostenverzekeringen N.V. came as a result of the higher premiums in combination with lowering the discount on the voluntary deductible. In the years before 2018 Ditzo ranked higher in comparison with competitors.

Also De Amersfoortse experienced a decline in the number of insured persons in 2018. De Amersfoortse was the most expensive refund policy in the market. The total gross new Healthcare business of € 37.6 million (2017: € 58.1 million) is accounted for by Ditzo for 78.1% (2017: 82%).

Gross written premiums

Gross written premiums increased to € 621 million (2017: € 589 million). The turnover is higher than in 2017 despite a shrinking of the portfolio. This is mainly caused by the premium increase in 2018, lowering the discount in voluntary deductible and no provision for a premium shortfall was formed.

Combined ratio

The claims ratio and the combined ratio improved compared to last year. This development is due to the rise of the earned premium in 2018. Also the result for prior years was more positive in 2018. The commission ratio did improve by lower cost of acquisition compared to 2017. The expense ratio is stabilized compared to 2017.

Solvency and liquidity at reporting date

Overall capital management is administered at group level. The legal entities are capitalised separately. For ASR Basis Ziektekostenverzekeringen N.V. no upstreaming of capital to the group level is currently foreseen. All capital present is used for strengthening of the capital positioning, investments or to maintain a socially responsible pricing level.

The solvency ratio stood at 140% at 31 December 2018 (2017: 135%), which was comfortably higher than the lower limit solvency target of 130%.
A.3 Investment performance

ASR Basis Ziektekostenverzekeringen N.V.’s investment policy is aimed at striking a balance between generating returns and preventing risks. Protecting the solvency position is an important factor in this context.

A.3.1 Financial assets and derivatives

<table>
<thead>
<tr>
<th>Investments</th>
<th>31 December 2018</th>
<th>31 December 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investments</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Available for sale</td>
<td>203,149</td>
<td>187,942</td>
</tr>
<tr>
<td>Total investments</td>
<td>203,149</td>
<td>187,942</td>
</tr>
</tbody>
</table>

Based on their contractual maturity, an amount of € 147 million (2017: € 163 million) of fixed income investments, asset-backed securities and other investments is expected to be recovered after twelve months after reporting date.

For all assets without a contractual maturity date, it is assumed that they will be expected to be recovered after twelve months after the reporting date.

Investment income

<table>
<thead>
<tr>
<th>Breakdown of investment income per category</th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interest income from investments</td>
<td>1,139</td>
<td>1,640</td>
</tr>
<tr>
<td>Other interest income</td>
<td>14</td>
<td>-38</td>
</tr>
<tr>
<td>Interest income</td>
<td>1,153</td>
<td>1,602</td>
</tr>
<tr>
<td>Dividend on equities</td>
<td>184</td>
<td>151</td>
</tr>
<tr>
<td>Dividend and other investment income</td>
<td>184</td>
<td>151</td>
</tr>
<tr>
<td>Total investment income</td>
<td>1,338</td>
<td>1,753</td>
</tr>
</tbody>
</table>

The effective interest method has been applied to an amount of € 1,139 thousand of the interest income from financial assets not classified at fair value through profit or loss (2017: € 1,640 thousand).

Interest income includes nil (2017: € 39 thousand) in interest received on impaired fixed-income securities.
A.3.2 Company statement of comprehensive income

### Consolidated statement of comprehensive income for the year ended 31 December

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Profit for the year</td>
<td>-957</td>
<td>-2,129</td>
</tr>
<tr>
<td>Unrealised change in value of available for sale assets</td>
<td>-2,468</td>
<td>129</td>
</tr>
<tr>
<td>Realised gains/(losses) on available for sale assets reclassified to profit or loss</td>
<td>-738</td>
<td>-2,246</td>
</tr>
<tr>
<td>Income tax on items that may be reclassified subsequently to profit or loss</td>
<td>801</td>
<td>530</td>
</tr>
<tr>
<td><strong>Total items that may be reclassified subsequently to profit or loss</strong></td>
<td><strong>-2,404</strong></td>
<td><strong>-1,587</strong></td>
</tr>
<tr>
<td><strong>Total other comprehensive income for the year, after tax</strong></td>
<td><strong>-2,404</strong></td>
<td><strong>-1,587</strong></td>
</tr>
<tr>
<td><strong>Total comprehensive income</strong></td>
<td><strong>-3,361</strong></td>
<td><strong>-3,716</strong></td>
</tr>
</tbody>
</table>

A.3.3 Information about investments in securities

As ASR Basis Ziektekostenverzekeringen N.V. has no investments in securitization, no further information is included here.

A.4 Performance of other activities

No other activities are material.

A.5 Any other information

No other information is applicable.
In the case where the text below refers to ‘the company’, ASR Basis Ziektekostenverzekeringen N.V. is meant.

B.1 General information on the system of governance

B.1.1 Corporate governance

ASR Basis Ziektekostenverzekeringen N.V. has an Executive Board and a Supervisory Board.

Executive Board
The Executive Board is responsible for the company’s management, meaning that it is responsible for aspects such as achieving corporate objectives, the strategy and the associated risk profile, and the ensuing financial performance of the company and its subsidiaries.

The General Meeting of Shareholders appoints the members of the Executive Board and may suspend or dismiss any member of the Executive Board at any time. The Supervisory Board may also suspend any member of the Executive Board. A suspension by the Supervisory Board may be initiated by the General Meeting of Shareholders at any time. a.s.r. aims to have an adequate and balanced composition of the Executive Board. The Executive Board in 2018 consisted of two members, one woman and one man. In 2017, the Supervisory Board adopted a formal diversity policy. a.s.r. uses the following definition for diversity: a balanced composition of the workforce, based on age, gender, cultural or social origin, competences, views and working styles. One of the objectives is an Executive Board consisting of at least 30% women and at least 30% men. The current composition of the Executive Board does meet both goals regarding the gender balance of the Executive Board.

Supervisory Board
The Supervisory Board is responsible for overseeing, checking (also proactively) and advising the Executive Board with regard to achieving the corporate objectives, the strategy and the risks associated with the company’s business activities.

The Supervisory Board consists of four members. The General Meeting of Shareholders appoints the members of the Supervisory Board and may suspend or dismiss any member of the Supervisory Board at any time.

B.1.1.1 Supervisory Board Committees

Audit and Risk Committee
The Supervisory Board did not institute an Audit and Risk Committee.

Remuneration Committee
The Supervisory Board did not institute a Remuneration Committee.

Selection & Appointment Committee
The Supervisory Board did not institute a Selection, Appointment and Remuneration Committee.

B.1.1.2 Corporate Governance

ASR Basis Ziektekostenverzekeringen N.V. is a limited liability company. The company has a two-tier board; a Supervisory Board and an Executive Board. The General Meeting of Shareholders is authorized to appoint and dismiss members of the Executive Board and the Supervisory Board.

B.1.1.3 Executive Board

The Executive Board is responsible for the day-to-day conduct of business of ASR Basis Ziektekostenverzekeringen N.V. and for the strategy, structure and performance. In performing their duties the Executive Board is guided by ASR Basis Ziektekostenverzekeringen N.V.’s interests, which include the interests of the business connected with ASR Basis Ziektekostenverzekeringen N.V., which, in turn, include the interests of customers, insurers, employees and, in general, the society in which ASR Basis Ziektekostenverzekeringen N.V.’s business is carried out. The Executive Board is accountable for the performance of its duties to the Supervisory Board and to the General Meeting.

Composition
The Executive Board will consist of a minimum of two members. The General Meeting of Shareholders appoints the Executive Board members and may at any time suspend or dismiss any member of the Executive Board. Only candidates found to meet the fit and proper test under the Dutch Financial Markets Supervision Act are eligible for appointment. The Executive Board consists of J.M. Hendriks and J.D. Lansberg. The composition of the Executive Board remained unchanged in 2018.
Education and evaluation Executive Board of the group
The members of the Executive Board followed individual programs in 2018 as part of their continuing education (CE). In addition, much attention was devoted to knowledge-development in the areas of risk, capital management and strategic challenges, including the impact of political decisions on the potential business models of health care insurers in The Netherlands.

The decision making process of the Executive Board was self-evaluated in 2018 and discussed with the deputy directors. Goal of the evaluation and discussion was to find useful elements and ways to further enhance the effective decision-making and information gathering. In addition to the self-evaluation, the performance of the members of the Executive Board was also assessed by the Supervisory Board.

B.1.1.4 Supervisory Board
The Supervisory Board supervises the policy pursued by the Executive Board and the general course of affairs at ASR Basis Ziektekostenverzekeringen N.V. and advises the Executive Board. Specific powers are vested in the Supervisory Board, including the approval of certain decisions taken by the Executive Board.

Composition
The Supervisory Board of ASR Basis Ziektekostenverzekeringen N.V. consists of four members: C. van der Pol (chairman), A.P. Aris, J.P.M. Baeten and M.H. Verwoest. The Supervisory Board has drawn up a profile for its size and composition, taking into account the nature of ASR Basis Ziektekostenverzekeringen N.V’s business, its activities and the desired expertise and background of the Supervisory Board members.

The composition of the Supervisory Board is such that each supervisory director should have the skills to assess the main aspects of the overall policy and that the Supervisory Board as a whole meets the profile thanks to a combination of the experience, expertise and independence of the individual supervisory directors. The Supervisory Board is diverse in terms of the gender and professional background of its members. The diversity of its members ensures the complementary profile of the Supervisory Board.

Education and evaluation Supervisory Board of the group
The Supervisory Board performs an annual self-assessment. A self-assessment with external guidance is carried out every three years. The assessment was based on a dedicated meeting of the supervisory board. The following aspects were assessed:
- Composition of the Supervisory Board;
- Communication, information-gathering and decision-making;
  Their role as advisor of the Executive Board;
- Their role as employer of the Executive Board.
The outcome of the assessment was discussed in a formal meeting of the Supervisory with the Executive Board. The overall impression that emerged from this self-assessment was positive. The Supervisory Board is seen as a properly operating group in terms of content, with a balanced and high-quality composition. The atmosphere is open and the relationship with the Executive Board is good. One recommendation made was to improve an open dialogue on relevant strategic issues at an early stage to strengthen the role as advisor of the board.

In 2018, two continuing education (CE) session were organised for the members of the Supervisory Board together with the members of the Executive Board and senior managers. The first session concerned a follow-up on the explanation of IFRS 17, the new accounting standard for insurance contracts, led by Group Accounting, Reporting & Control. The new regulations will impact the external reporting on insurance contracts in the future. The implementation of IFRS 17 within a.s.r. is a major project. The second session focused on an increasing digitisation in the insurance industry. Thirdly, a knowledge session led by an external expert on governance and board leadership took place. During this session, the Supervisory and the Executive Board received an update on long-term value creation according to the Dutch Corporate Governance Code and elaborated on this topic in relation to a.s.r. Furthermore, the individual members of the Supervisory Board received updates and presentations on various topics due to their supervisory directorships at several Dutch and foreign enterprises and institutions.

B.1.1.5 Corporate Governance Codes and regulations
Dutch Health Insurers Code Code
ASR Basis Ziektekostenverzekeringen is subject to the Dutch Health Insurers Code (2012). This code contains principles for governance. Specifically, it defines guidelines for the fulfillment of the public responsibility regarding the execution of the compulsory Dutch Health Insurance Act. Every year, ASR Basis Ziektekostenverzekeringen N.V. accounts it performance to the Dutch Healthcare Authority.

Professional oath
On 1 January 2013, the Dutch financial sector introduced a mandatory oath for Executive and Supervisory Board members of financial institutions licensed in the Netherlands. With respect to insurance companies, apart from the Executive and Supervisory Board members, persons with a management position directly below the Executive Board who are responsible for persons that may have a significant influence on the risk profile of the insurance company, are also required to take the oath, as are certain other employees. This includes persons that may (independently) significantly influence the risk profile of the undertaking as well as those persons that are or may be involved in the provision of financial services.

Regardless of the above, a.s.r. has decided that all employees and other persons performing activities under its responsibility must take the oath. New employees take the oath within three months of joining the company.
B.1.2 Related-party transactions

A related party is a person or entity that has significant influence over another entity, or has the ability to affect the financial and operating policies of the other party. Parties related to ASR Basis Ziektekostenverzekeringen N.V. include ASR Nederland N.V. and its subsidiaries, NLFI and the Dutch State for the period until 13 September 2017, members of the Executive Board, members of the Supervisory Board, close family members of any person referred to above, entities controlled or significantly influenced by any person referred to above and any other affiliated entity.

ASR Basis Ziektekostenverzekeringen N.V. regularly enters into transactions with related parties during the conduct of its business. These transactions mainly involve loans and receivables, subordinated liabilities and allocated expenses, and are conducted on terms equivalent to those that prevail in arm’s length transactions.

- The remuneration of the Executive Board and Supervisory Board of ASR Basis Ziektekostenverzekeringen N.V. are described in chapter 2.6.6;
- The operating expenses, reported in chapter 2.5.6, are predominantly intercompany, consisting of allocated expenses from head office, support functions and expenses related to personnel;
- Transactions with ASR Nederland N.V. concern the payment of taxes as ASR Nederland N.V. heads the fiscal unity. Reference is made to chapter 2.6.7.

Positions and transactions between ASR Basis Ziektekostenverzekeringen N.V. and the related parties

### Financial scope of a.s.r.’s related party transactions

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Balance sheet items with related parties as at 31 December</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Loans and receivables</td>
<td>5,381</td>
<td>17,191</td>
</tr>
<tr>
<td>Subordinated liabilities</td>
<td>10,000</td>
<td>10,000</td>
</tr>
<tr>
<td><strong>Transactions in the income statement for the financial year</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interest expense</td>
<td>667</td>
<td>637</td>
</tr>
</tbody>
</table>

B.1.3 Remuneration of Supervisory Board and Executive Board

No provisions for impairments have been recognised on the loans and receivables for the years 2018 and 2017. No loans were provided by ASR Basis Ziektekostenverzekeringen N.V. to the Executive Board.

### Annual remuneration for members of the Supervisory Board

<table>
<thead>
<tr>
<th>Supervisory Board member</th>
<th>Amounts in € thousand</th>
<th>2018</th>
<th>WNT Maximum</th>
<th>2017</th>
<th>WNT Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>C. van der Pol</td>
<td></td>
<td>3</td>
<td>36</td>
<td>-</td>
<td>35</td>
</tr>
<tr>
<td>A.P. Aris</td>
<td></td>
<td>1</td>
<td>24</td>
<td>-</td>
<td>23</td>
</tr>
<tr>
<td>J.P.M. Baeten</td>
<td></td>
<td>-</td>
<td>24</td>
<td>-</td>
<td>23</td>
</tr>
<tr>
<td>M.H. Verwoest</td>
<td></td>
<td>-</td>
<td>24</td>
<td>-</td>
<td>23</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td>4</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

The annual remuneration for the members of the Supervisory Board is accounted for in the remuneration paragraph of the annual report of ASR Nederland N.V. In 2018 only the amount of compensation paid for the services provided by the Supervisory Board members C. van der Pol and A.P. Aris were charged to ASR Basis Ziektekostenverzekeringen N.V., and is subsequently accounted for in the result of ASR Basis Ziektekostenverzekeringen N.V.

B.1.3.1 Remuneration of Supervisory Board members

The remuneration policy of the Executive and Supervisory Board members is determined in accordance with the current Articles of Association of ASR Nederland N.V.

B.1.3.2 Remuneration of current and former Executive Board members

The remuneration of current and former members is in accordance with the 2018 remuneration policy.

In accordance with the remuneration law 'Wet aansprakelijkheidsbeperking DNB en AFM en bonusverbod staatsgesteunde ondernemingen', issued by the Dutch government, no variable remuneration has been disbursed to the Executive Board members for the period...
as from the 2014 ASR Basis Ziektekostenverzekeringen N.V. financial year until the current 2018 ASR Basis Ziektekostenverzekeringen N.V. financial year.

The Executive Board of ASR Basis Ziektekostenverzekeringen N.V. is also the Executive Board of ASR Aanvullende Ziektekostenverzekeringen N.V. In the table below the total costs of the Executive Board are presented of which 72,14% (2017: 72,14%) is allocated to ASR Basis Ziektekostenverzekeringen N.V. and 27,86% (2017: 27,86%) to ASR Aanvullende Ziektekostenverzekeringen N.V. respectively.

### Annual remuneration for members of the Executive Board

<table>
<thead>
<tr>
<th>Executive Board member</th>
<th>Fixed employee benefits</th>
<th>Pension benefits²</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2018</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>drs. J.M. Hendriks RA*</td>
<td>126</td>
<td>25</td>
<td>151</td>
</tr>
<tr>
<td>drs. J.D. Lansberg**</td>
<td>173</td>
<td>26</td>
<td>199</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>299</strong></td>
<td><strong>51</strong></td>
<td><strong>350</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Executive Board member</th>
<th>Fixed employee benefits</th>
<th>WNT maximum³</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2018</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>drs. J.M. Hendriks RA*</td>
<td>126</td>
<td>173</td>
<td></td>
</tr>
<tr>
<td>drs. J.D. Lansberg**</td>
<td>173</td>
<td>173</td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>299</strong></td>
<td><strong>346</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Executive Board member</th>
<th>Fixed employee benefits</th>
<th>Pension benefits²</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2017</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>drs. J.M. Hendriks RA*</td>
<td>121</td>
<td>28</td>
<td>149</td>
</tr>
<tr>
<td>drs. J.D. Lansberg**</td>
<td>114</td>
<td>135</td>
<td></td>
</tr>
<tr>
<td>drs. J.D. Lansberg**</td>
<td>56</td>
<td>66</td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>291</strong></td>
<td><strong>59</strong></td>
<td><strong>350</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Executive Board member</th>
<th>Fixed employee benefits</th>
<th>WNT maximum³</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2017</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>drs. J.M. Hendriks RA*</td>
<td>121</td>
<td>169</td>
<td></td>
</tr>
<tr>
<td>drs. J.D. Lansberg**</td>
<td>114</td>
<td>152</td>
<td></td>
</tr>
<tr>
<td>drs. J.D. Lansberg**</td>
<td>56</td>
<td>56</td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>291</strong></td>
<td><strong>377</strong></td>
<td></td>
</tr>
</tbody>
</table>

1. This table is intended for top-level executives (and former top-level executives) with executive duties, i.e. the members of the highest executive body and their subordinates, and those tasked with the day-to-day management of the overall legal entity.
2. The decrease in annual pension expenses is caused by an increase of the interest rates. The calculation of the annual pension expenses is based on the total granted pension rights during the term of service at a.s.r. Further changes in the cost of pension benefits are mainly the result of the impact of age, term of service, gender and age differentiated disability, mortality and other actuarial assumptions. The pension costs include pensions based on maximum pensionable salary cap, compensation for maximum pensionable salary cap (at employee discretion to be utilised for pensions considered short term employee benefits) amounting to € 19 thousand (2017: € 17 thousand) in total, and VPL. The Pension benefits, excluding pensions based on maximum pensionable salary cap, represent post-employment benefits.
3. $y = (x \cdot a \cdot b)/365$ where: $x =$ WNT remuneration cap applicable to institution, $a =$ part-time factor (maximum 1.0 FTE) and $b =$ term of service in calendar days.

* In function from 1 January 2018 until 31 December 2018.
** In function from 1 January 2018 until 31 December 2018.
Correction of prior period error

The executive board are employed by ASR Nederland N.V. and therefore qualify at ASR Basis Ziektekostenverzekeringen N.V as an executive board members without employment. The remuneration recognised in the WNT at ASR Basis Ziektekostenverzekeringen N.V amounts to the costs charged to ASR Basis Ziektekostenverzekeringen N.V for the fulfilment of the function of executive board member at ASR Basis Ziektekostenverzekeringen N.V. The costs charged consist of wage costs including employer’s social security costs and any lease car costs.

The comparative figures have been adjusted compared to the WNT disclosure in the 2017 financial statements. In the WNT disclosure included in the 2017 financial statements, the total remuneration of the executive board members was included. The adjusted comparative figures for WNT remuneration 2017 follow the procedure as described above, so the costs charged to ASR Basis Ziektekostenverzekeringen N.V. for the fulfilment of the function of executive board of ASR Basis Ziektekostenverzekeringen N.V. A distinction has also been made for executive board members without employment for the first twelve months of employment (until 1 September 2017) and executive board members without employment from the thirteenth month of function fulfilment (from 1 September 2017).

The differences disclosed below include, next to the adjustments in remuneration of the executive board members, the adjustments of the part-time factor (based on % wage costs charged). The remuneration maximum applicable to the institution has been adjusted accordingly.

The adjusted WNT remuneration for 2017 has led to J.D. Lansberg exceeding the individual remuneration maximum. Transitional rule does not apply to the higher WNT remuneration, as a result of which the adjusted remuneration has led to an undue payment of € 1,191. This amount was fully repaid through settlement in the current account with ASR Nederland N.V. The adjusted WNT remuneration has not led to exceedance of the remuneration maximum for the other executive board member.

### Annual remuneration for members of the Executive Board

<table>
<thead>
<tr>
<th>Executive Board member¹</th>
<th>Fixed employee benefits</th>
<th>Pension benefits</th>
<th>Total</th>
<th>WNT maximum</th>
<th>Fixed employee benefits</th>
<th>Pension benefits</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Corrected</td>
<td>Corrected</td>
<td>Corrected</td>
<td>Prior Year</td>
<td>Corrected</td>
<td>Prior Year</td>
<td>Corrected</td>
</tr>
<tr>
<td>drs. J.M. Hendriks RA</td>
<td>121</td>
<td>28</td>
<td>149</td>
<td>165</td>
<td>35</td>
<td>200</td>
<td></td>
</tr>
<tr>
<td>drs. J.D. Lansberg 1/1/2017-31/08/2017</td>
<td>114</td>
<td>21</td>
<td>135</td>
<td>234</td>
<td>35</td>
<td>269</td>
<td></td>
</tr>
<tr>
<td>drs. J.D. Lansberg 1/9/2017-31/12/2017</td>
<td>56</td>
<td>10</td>
<td>66</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>P.H. van Holst-Wormser*</td>
<td>-</td>
<td>-</td>
<td>43</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>291</strong></td>
<td><strong>59</strong></td>
<td><strong>350</strong></td>
<td><strong>442</strong></td>
<td><strong>70</strong></td>
<td><strong>512</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Executive Board member¹</th>
<th>Fixed employee benefits</th>
<th>WNT maximum</th>
<th>Fixed employee benefits</th>
<th>WNT maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Corrected</td>
<td>Prior Year</td>
<td>Corrected</td>
<td>Prior Year</td>
</tr>
<tr>
<td>drs. J.M. Hendriks RA</td>
<td>149</td>
<td>169</td>
<td>165</td>
<td>234</td>
</tr>
<tr>
<td>drs. J.D. Lansberg 1/1/2017-31/08/2017</td>
<td>114</td>
<td>152</td>
<td>234</td>
<td>234</td>
</tr>
<tr>
<td>drs. J.D. Lansberg 1/9/2017-31/12/2017</td>
<td>56</td>
<td>56</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>P.H. van Holst-Wormser*</td>
<td>-</td>
<td>-</td>
<td>43</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>291</strong></td>
<td><strong>377</strong></td>
<td><strong>442</strong></td>
<td><strong>468</strong></td>
</tr>
</tbody>
</table>
B.2 Fit and proper requirements

The policy pursued by a.s.r. concerning fit and proper requirements for persons who effectively run the undertaking and other key functions contributes to a controlled and sound business operations and promotes the stability and integrity of a.s.r. as well as customer confidence.

The fit and proper requirements that are imposed on persons who effectively run the undertaking and other key functions are included in the job profile, which is used as a basis for recruitment. Each year, an assessment is made of the extent to which an employee requires training to perform its duties. In addition, a.s.r. has a program for the continuing education of persons who effectively run the undertaking and other key functions. a.s.r. assesses all prospective employees for their reliability and integrity prior to their appointment.

B.3 Risk management system including the Own Risk and Solvency Assessment Risk Management System

This paragraph contains a description of group policy, which is applicable for the solo entity. It is of great importance to a.s.r. that risks within all business lines are timely and adequately controlled. In order to do so, a.s.r. has implemented a Risk Management framework based on internationally recognized and accepted standards (such as COSO ERM and ISO 31000:2018 risk management principles and guidelines). Using this framework, material risks that a.s.r. is, or can be, exposed to, are identified, measured, managed, monitored and evaluated. The framework is both applicable to a.s.r. group and the underlying (legal) business entities.

B.3.1 Risk Management Framework

The figure below is the risk management framework as applied by a.s.r. The framework is based on the Enterprise Risk Management (ERM) model by COSO¹.

¹ ISO 31000:2018 risk management principles and guidelines.
Risk Management Framework

The Risk Management (RM) framework consists of risk strategy (including risk appetite), risk governance, systems and data, risk policies and procedures, risk culture, and risk management process. The RM framework contributes to achieving the strategic objectives as set out by a.s.r.

Risk strategy (incl. risk appetite)
Risk strategy is defined to contain at least the following elements:
- Strategic objectives that are pursued;
- The risk appetite in pursuit of those strategic objectives.

a.s.r.’s risk strategy aims to ensure that decisions are made within the boundaries of the risk appetite, as stipulated annually by the Executive Board and the Supervisory Board (see chapter B.3.1.1 Risk strategy and risk appetite).

Risk governance
Risk governance can be seen as the way in which risks are managed, through a sound risk governance structure and clear tasks and responsibilities, including risk ownership. a.s.r. employs a risk governance framework that entails the tasks and responsibilities of the risk management organization and the structure of the Risk committees (see chapter B.3.1.2 Risk governance).

Systems and data
Systems and data support the risk management process and provide management information to the risk committees and other relevant bodies. Strategic decisions are based on the management information provided. a.s.r. finds it very important to have qualitatively adequate data and systems in place, in order to be able to report and steer correct figures and to apply risk-mitigating measures timely. To ensure this, a.s.r. has designed a policy for data quality in line with Solvency II. Tools, models and systems are implemented to support the risk management process by giving guidance to and insights into the key risk indicators, risk tolerance levels, boundaries and actions, and remediation plans to mitigate risks (see chapter B.3.1.3 Systems and data).

Risk policies and procedures:
Risk policies and procedures at least:
- Define the risk categories and the methods to measure the risks;
- Outline how each relevant category, risk area and any potential aggregation of risk is managed;
- Describe the connection with the overall solvency needs assessment as identified in the Own Risk & Solvency Assessment (ORSA), the regulatory capital requirements and the risk tolerances;
- Provide specific risk tolerances and limits within all relevant risk categories in line with the risk appetite statements;
- Describe the frequency and content of regular stress tests and the circumstances that would warrant ad-hoc stress tests.

The classification of risks within a.s.r. is performed in line with, but is not limited to, the Solvency II risks. Each risk category consists of a policy that explicates how risks are identified, measured and controlled within a.s.r. (see chapter B.3.1.4 Risk policies and procedures).

Risk culture
An effective risk culture is one that enables and rewards individuals and groups for taking risks in an informed manner. It is a term describing the values, beliefs, knowledge, attitudes and understanding about risk. All the elements of the RM framework combined make an effective risk culture.

Within a.s.r. risk culture is an important element that emphasizes the human side of risk management. The Executive Board has a distinguished role in expressing the appropriate norms and values (tone at the top). a.s.r employs several measures to increase the risk awareness and, in doing so, the risk culture (see chapter B.3.1.5 Risk culture).

Risk management process
The risk management process contains all activities within the RM processes to structurally 1) identify risks; 2) measure risks; 3) manage risks; 4) monitor and report on risks; and 5) evaluate the risk profile and risk management framework. At a.s.r., the risk management process is used to implement the risk strategy in the steps mentioned. These five steps allow for the risks within the company to be managed effectively (see chapter B.3.1.6 Risk Management process).

B.3.1.1 Risk management strategy and risk appetite
This paragraph discusses the risk appetite of ASR Basis Ziektekostenverzekeringen N.V. and is derived from the policy document Capital and Dividend Policy of ASR Basis Ziektekostenverzekeringen N.V. and ASR Aanvullende Ziektekostenverzekeringen N.V.

ASR Basis Ziektekostenverzekeringen N.V. belongs to the insurance group a.s.r. Nederland. a.s.r. Nederland has a capital and dividend policy that enables the group to steer towards the financial stability of the group in a structured and balanced manner. Under the articles of association, ASR Basis Ziektekostenverzekeringen N.V. has its own responsibility for the capital position. A (limited) transition is therefore necessary in order to make the capital policy of the umbrella group applicable to a.s.r Zorg. As far as possible, these choices are made in line with the policy of a.s.r. Nederland.

The aim of this policy is to establish a stable, consistent and predictable policy for the management of capital within ASR Basis Ziektekostenverzekeringen N.V. in order to promote the company’s stability and continuity so as to meet the obligations towards policyholders at all times.

Each year, specific objectives (management target) and risk limits (risk appetite) for the capital position of ASR Basis Ziektekostenverzekeringen N.V. are set by the Executive Board, with the approval of the Supervisory Board.

A solvency objective (management target) reflects the level of solvency sought and contains a reasonable buffer above the internal limits of the risk appetite statement. The difference between the limits of the risk appetite statement and the objectives (management target) is that a limit is very strict and that breaking a limit will have to be remedied immediately, whereas an objective is a long-term target value.

B.3.1.1.1 Substantiation and structure of limits and objectives for the solvency of a.s.r.
The objectives and limits are set annually by the Executive Board of ASR Basis Ziektekostenverzekeringen N.V. based on the principles for capital management as laid down in the capital policy. Under certain circumstances, and with the approval of the Supervisory Board of ASR Basis Ziektekostenverzekeringen N.V., substantiated deviations from these principles may be made.

The objectives and limits are agreed with the Executive Board and the Supervisory Board of a.s.r. Nederland in order to ensure the consistency of the capital policy within the group. Of course, this working method does not affect the personal responsibility of the ASR Basis Ziektekostenverzekeringen N.V. Executive Board members under the articles of association.

B.3.1.2 Risk governance
a.s.r.‘s risk governance can be described by:
• Risk ownership;
• the implemented three lines of defence model and associated (clear delimitation of) tasks and responsibilities of key function holders; and
• the risk committee structure to ensure adequate strategic decision making.

Risk ownership
The Executive Board has the final responsibility for risk exposures and management within the organization. Part of the responsibilities have been delegated to persons that manage the divisions where the actual risk-taking takes place. Risk owners are accountable for one or more risk exposures that are inextricably linked to the department or product line they are responsible for. Through the risk committee structure, risk owners provide accountability for the risk exposures.
### Three lines of defence

The risk governance structure is based on the ‘three lines of defence’ model. The ‘three lines of defence’ model consists of three defence lines with different responsibilities with respect to the ownership of controlling risks. The model below provides insight in the organization of the three lines of defence within a.s.r.

<table>
<thead>
<tr>
<th>First line of defence</th>
<th>Second line of defence</th>
<th>Third line of defence</th>
</tr>
</thead>
</table>
| • Executive Board     | • Group Risk Management department  
  - Risk management function  
  - Actuarial function  
  • Integrity department  
  - Compliance function  |
| • Management teams of the business lines and their employees  
  • Finance & risk decentral  |
| Ownership and implementation  |
| Policies and monitoring implementation by 1st line  |
| Independent assessment of 1st and 2nd lines  |

- **First line of defence**
  - Responsible for the identification and the management of risks in the daily business
  - Has the day-to-day responsibility for operations (sales, pricing, underwriting, claims handling, etc.) and is primarily responsible for implementing risk frameworks and policies.

- **Second line of defence**
  - Challenges the 1st line and supports the 1st line to achieve their business objectives in accordance with the risk appetite
  - Has sufficient countervailing power to prevent risk concentrations and other forms of excessive risk taking
  - Responsible for developing risk policies and monitoring the compliance with these policies

- **Third line of defence**
  - Responsible for providing dedicated assurance services and oversees and assesses the functioning and the effectiveness of the first two lines of defence
Positioning of key functions
Within the risk governance, the key functions (compliance, risk, actuarial and audit) are organized in accordance with Solvency II regulation and play an important role as countervailing power of management in the decision-making process. The four key functions are independently positioned within a.s.r. In all the risk committees one or more key functions participate. None of the functions has voting rights in the committees, in order to remain fully independent as countervailing power. All functions have direct communication lines with the Executive Board and can escalate to the chairman of the Audit & Risk Committee of the Supervisory Board. Furthermore, the key functions have regular meetings with the supervisors of the Dutch Central Bank and/or The Dutch Authority for the Financial Markets (AFM).

Group Risk Management
Group Risk Management is responsible for the execution of the risk management function and the actuarial function. The department is led by the CRO. Group Risk Management consists of the following sub-departments:
- Enterprise Risk Management;
- Financial Risk Management (including Actuarial Function).

Enterprise Risk Management
Enterprise Risk Management is responsible for second-line operational (including IT) risk management and the enhancement of the risk awareness for a.s.r. and its subsidiaries. The responsibilities with regards to enterprise risk management include the development of risk policies, the annual review and update of the risk strategy (risk appetite), the coordination of the SRA process leading to the risk priorities and ORSA scenarios and the monitoring of the non-financial strategic risk profile. For the management of operational risks, a.s.r has a solid Risk-Control framework in place that contributes to its long-term solidity. The RMF monitors and reviews the non-financial operational risk profile. The quality of the framework is continuously enhanced by the analysis of operational incidents, periodic assessments and monitoring by the RMF. Enterprise Risk Management actively promotes risk awareness at all levels to contribute to the vision of staying a socially relevant insurer.

Financial Risk Management
Financial Risk Management (FRM) is responsible for the second line financial risk management and supports both the Actuarial Function and Risk Management Function. An important task of FRM is to be the countervailing power to the Executive Board and management in managing financial risks for a.s.r. and its subsidiaries. FRM assesses the accuracy and reliability of the market risk, counterparty risk, insurance risk and liquidity risk, risk margin and best estimate liability. Other responsibilities are model validation and policies on valuation and risk. FRM is also responsible for the actuarial function. As part of the actuarial function, FRM reviews the technical provisions, monitors methodologies, assumptions and models used in these calculations, and assesses the adequacy and quality of data used in the calculations. Furthermore, the Actuarial Function expresses an opinion on the underwriting policy and determines if risks related to the profitability of new products are sufficiently addressed in the product development process. The actuarial function also expresses an opinion on the adequacy of reinsurance arrangements.

Compliance
Compliance is responsible for the execution of the compliance function. An important task of Compliance is to be the countervailing power to the Executive Board and management in managing compliance risks for a.s.r. and its subsidiaries. The mission of the compliance function is to enhance and ensure a controlled and sound business operations where impeccable, professional conduct is self-evident.

As second line of defence, Compliance encourages the organization to comply with relevant rules and regulations, ethical standards and the internal standards derived from them (‘rules’) by providing advice and devising policy. Compliance supports the first line in the identification of compliance risks and assesses the effectiveness of risk management on which Compliance reports to the relevant risk committees. In doing so, Compliance uses a compliance risk and monitoring framework. In line with risk management, Compliance also creates further awareness in order to promote a culture of integrity. Compliance coordinates contacts with regulators in order to maintain an effective relationship and keeps oversight of the current topics.

Audit
The Audit department, the third line of defence, provides an independent opinion on governance, risk and management processes, with the goal of supporting the Executive Board and other management of a.s.r. in achieving the corporate objectives. To that end, Audit evaluates the effectiveness of governance, risk and management processes, and provides pragmatic advice that can be implemented to further optimize these processes. In addition, senior management can engage Audit for specific advisory projects.

Risk committee structure
a.s.r. has established a structure of risk committees with the objective to monitor the risk profile for a.s.r. group, its legal entities and its business lines in order to ensure that it remains within the risk appetite and the underlying risk tolerances and risk limits. When triggers are hit or likely to be hit, risk committees make decisions regarding measures to be taken, being risk-mitigating measures or measures regarding governance, such as the frequency of their meetings. For each of the risk committees a statute is drawn up in which the tasks, composition and responsibilities of the committee are defined.
ASR Basis Ziektekostenverzekeringen N.V. uses the risk infrastructure of the Group (see below), and in addition has its own business risk committee. Both operational and financial risk are in scope of this committee.

**Risk committee structure**

[Diagram showing the structure of risk committees and their interactions]

**Audit & Risk Committee**
The Audit & Risk Committee was established by the Supervisory Board to gain support in the following matters:
- Assessment of the risk appetite proposal based on the financial and non-financial risk reports, among other documents;
- Assessment of the annual report, including the financial statements of ASR Nederland N.V.;
- The relationship with the independent external auditor, including the assessment of the qualities and independence of the independent external auditor and the proposal by the Supervisory Board to the AGM to appoint the independent external auditor;
- The performance of the audit function, compliance function, the actuarial function and the risk management function;
- Compliance with rules and regulations; and
- The financial position.

The Audit & Risk Committee has three members of the RvC, one of whom acts as the chairman.

**a.s.r. Risk Committee**
The a.s.r. Risk Committee (a.s.r. RC) monitors a.s.r.'s overall risk profile on a quarterly basis. At least annually, the a.s.r. RC determines the risk appetite statements, limits and targets for a.s.r. This relates to the overall a.s.r. risk appetite and the subdivision of risk appetite by financial and non-financial risks. The risk appetite is then submitted to the a.s.r. Audit & Risk Committee, which advises the Supervisory Board on the approval of the risk appetite. The a.s.r. RC also monitors the progress made in managing risks included in the Risk Priorities of the Executive Board.

All members of the Executive Board participate in the a.s.r. RC, which is chaired by the CEO. The involvement of the Executive Board ensures that risk decisions are being addressed at the appropriate level within the organization. In addition to the Executive Board, the CRO, Director of Audit and Director of Integrity are members of the Committee.

**Non-Financial Risk Committee**
The Non-Financial Risk Committee (NFRC) discusses, advises and decides upon non-financial risk policies. The most relevant risk policies are approved by the a.s.r. RC. The NFRC monitors that non-financial risks are managed adequately and monitors that the risk profile stays within the agreed risk limits.

**Financial Risk Committee**
The Financial Risk Committee (FRC) discusses and decides upon financial risk policies. The most relevant financial risk policies are approved by the a.s.r. RC. The FRC monitors and controls financial risks (market, insurance (life and non-life) and counterparty default risk). The FRC
also monitors whether the risk profile stays within the risk limits. If the risk profile exceeds these limits, the FRC takes mitigating actions. The FRC reports to the a.s.r. Risk Committee. The Chairman of the FRC is the CFO.

**Capital, Liquidity and Funding Committee**
The Capital, Liquidity and Funding Committee (CLFC) is a subcommittee of the FRC. As such, the CLFC prepares and assesses the technical analysis of capital, liquidity and funding positions, rating policy, rating model reporting, and treasury activities. The Chairman of the CLFC is the Director of Group Asset Management.

**Model Validation Committee**
The model validation committee (MVC) is a subcommittee of the FRC and is responsible for the execution and update of the model validation policy and the approval of validation of existing or newly developed models. The MVC receives all required information for the validation of models (e.g. model documentation and validation reports) prepared by the validation board (MVB) that assures the quality of the validation process. The chairman of the MVC is the CRO.

**Business Risk Committees**
The business lines manage and control their risk profile through the Business Risk Committees (BRC). The BRC's monitor that the risk profile of the business lines stays within the risk appetite, limits and targets, as formulated by the Executive Board. The BRC reports to the FRC and the NFRC. The Chairman of the BRC is the Managing Director of the business line.

**Central Investment Committee**
In addition to the risk committee structure, the Central Investment Committee (CIC) monitors tactical decisions and the execution of the investment policy. It takes investment decisions within the boundaries of the strategic asset allocation as agreed upon in the FRC. The CIC bears particular responsibility for investment decisions exceeding the mandate of the investment department. The CIC is chaired by the COO Life (member of the Executive Board).

**Product Approval and Review Process Board**
The Product Approval & Review Process Board (PARP Board) is responsible for the final decision-making process around the introduction of new products and adjustments in existing products. The managing Director of the business line Health is appointed as chairman. The committee evaluates if potential risks in newly developed products are sufficiently addressed. New products need to be developed in such a way that they are cost efficient, reliable, useful and secure. New products also need to have a strategic fit with a.s.r.‘s mission to be a solid and trustful insurer. In addition, the risks of existing products are evaluated, as requested by the product approval and review process as a result of product reviews.

### B.3.1.3 Systems and data

GRC tooling is implemented to support the risk management process by giving guidance and insight into the key risk indicators, risk tolerance levels, boundaries and actions and remediation plans to mitigate risks. The availability, adequacy and quality of data and IT systems is important in order to ensure that correct figures are reported and risk mitigating measures can be taken in time. It is important to establish under which conditions the management information that is submitted to the risk committees has been prepared and which quality safeguards were applied in the process of creating this information. This allows the risk committees to ascertain whether the information is sufficient to base further decisions upon.

a.s.r. has a Data Governance and Quality policy in place to support the availability of correct management information. This policy is evaluated on an annual basis and revised at least every three years to keep the standards in line with the latest developments on information management. The quality of the information is reviewed based on the following aspects, based on Solvency II:

- Completeness (including documentation of accuracy of results);
- Adequacy;
- Reliability;
- Timeliness.

The preparatory body or department checks the assumptions made and the plausibility of the results, and ensures coordination with relevant parties. When a preparatory body has established that the information is reliable and complete, it approves and formally submits the document(s) to a risk committee.

The information involved tends to be sensitive. To prevent unauthorized persons from accessing it, it is disseminated using a secure channel or protected files. a.s.r.’s information security policy contains guidelines in this respect.

a.s.r.’s information security policy is based on ISO 27002 ‘Code of practice for information security management’. This Code describes best practices for the implementation of information security.

The aim of the information security policy is to take measures to ensure that the requirements regarding availability, reliability and integer and confidential use of systems and data are met:

- **Information availability** refers to the degree to which the information is at hand as soon as the organization needs it, meaning, for instance, that the information should be retrievable on demand and that it can be consulted and used at the right time;
- **The integrity, i.e. reliability, of information is the degree to which it is up-to-date, complete and error-free;**
- **‘Confidential use’ refers to the degree to which the information is available to authorized persons only and the extent to which it is not available to unauthorized persons.**
There are technical solutions for accomplishing this, by enforcing a layered approach (defence-in-depth) of technical measures to avoid unauthorized persons (i.e. hackers) to compromise a.s.r. corporate data and systems. In this perspective, one may think of methods of logical access management, intrusion detection techniques, in combination with firewalls are aimed at preventing hackers and other unauthorized persons from accessing information stored on a.s.r. systems. Nevertheless, confidential information can also have been committed to paper. In addition to technical measures there are physical measures and measures that helps the right awareness of personnel as part of the information security environment.

When user defined models (e.g. spreadsheets) are used for supporting the RM Framework, the ‘a.s.r. Standard for End user computing’ - in addition of the general security policy - defines and describes best practices in order to guard the reliability and confidentiality of these tools and models. a.s.r. recognizes the importance of sound data quality and information management systems. End 2018 a.s.r. finished the project to further enhance the measurement and reporting on data quality for the purposes of financial reporting.

The management of IT and data risks of the implemented tools, models and systems (including data) is part of the Operational IT risk management.

B.3.1.4 Risk policies and procedures

a.s.r. has established guidelines, including policies that cover all main risk categories (market, counterparty default, liquidity, underwriting, strategic and operational). These policies address the accountabilities and responsibilities regarding management of the different risk types.

Furthermore, the methodology for risk measurement is included in the policies. The content of the policies is aligned to create a consistent and complete set. The risk policy landscape is maintained by Group Risk Management and Compliance. These departments also monitor the proper implementation of the policies in the business. New risk policies or updates of existing risk policies are approved by the risk committees as mentioned previously.

B.3.1.5 Risk culture

Risk awareness is a vital component of building a sound risk culture within a.s.r. that emphasizes the human aspect in the management of risks. In addition to gaining sufficient knowledge, skills, capabilities and experience in risk management, it is essential that an organization enables objective and transparent risk reporting in order to manage them more effectively.

The Executive Board clearly recognizes the importance of risk management and is therefore represented in all of the major group level risk committees. Risk Management is involved in the strategic decision-making process, where the company's risk appetite is always considered. The awareness of risks during decision-making is continually addressed when making business decisions, for example by discussing and reviewing risk scenarios and the positive and/or negative impact of risks before finalizing decisions.

It is very important that this risk awareness trickles down to all parts of the organization, and therefore management actively encourages personnel to be aware of risks during their tasks and projects, in order to avoid risks or mitigate them when required. The execution of risk analyses is embedded in daily business in, for example, projects, product design and outsourcing.

In doing so, a.s.r. aims to create a solid risk culture in which ethical values, desired behaviours and understanding of risk in the entity are fully embedded. Integrity is of the utmost importance at a.s.r.: this is translated into a code of conduct and strict application policies for new and existing personnel, such as taking an oath or promise when entering the company, and the ‘fit and proper’ aspect of the Solvency II regulation, ensuring that a.s.r. is overseen and managed in a professional manner.

Furthermore, a.s.r. believes it is important that a culture is created in which risks can be discussed openly and where risks are not merely perceived to be negative and highlight that risks can also present a.s.r. with opportunities. Risk Management (both centralized and decentralized) is positioned as such, that it can communicate and report on risks independently and transparently, which also contributes to creating a proper risk culture.

B.3.1.6 Risk management process

The risk management process typically comprises of five important steps: 1) identifying; 2) measuring; 3) managing; 4) monitoring and reporting, and 5) evaluating\footnote{3 Based on COSO ERM and ISO 31000:2018.} a.s.r. has defined a procedure for performing risk analyses and standards for specific assessments. The five different steps are explained in this chapter.

Identifying

Management should endeavour to identify all possible risks that may impact the strategic objectives of a.s.r., ranging from the larger and/or more significant risks posed on the overall business, down to the smaller risks associated with individual projects or smaller business lines. Risk identification comprises of the process of identifying and describing risk sources, events, and the causes and effects of those events.

Measuring

After risks have been identified, quantitative or qualitative assessments of these risks take place to estimate the likelihood and impact associated with them. Methods applicable to the assessment of risks are:
\begin{itemize}
  \item Sensitivity analysis;
  \item Stress testing;
  \item Scenario analysis;
  \item Expert judgments (regarding likelihood and impact);
  \item Portfolio analysis.
\end{itemize}
Managing

Typically, there are five strategies to managing risk:
• Accept: risk acceptance means accepting that a risk might have consequences, without taking any further mitigating measures;
• Avoid: risk avoidance is the elimination of activities that cause the risk;
• Transfer: risk transference is transferring the impact of the risk to a third party;
• Mitigate: risk mitigation involves the mitigation of the risk likelihood and/or impact;
• Exploit: risk exploitation revolves around the maximization of the risk likelihood and/or increasing the impact if the risk does happen.

Risk management strategies are chosen in a way that ensures that a.s.r. remains within the risk appetite tolerance levels and limits.

Monitoring and reporting

The risk identification process is not a continuous exercise. Therefore, risk monitoring and reporting are required to capture changes in environments and conditions. This also means that risk management strategies could, or perhaps should, be adapted in accordance with risk appetite tolerance levels and limits.

Evaluating

The evaluation step is twofold. On the one hand, evaluation means risk exposures are evaluated against risk appetite tolerance levels and limits, taking (the effectiveness of) existing mitigation measures into account. The outcome of the evaluation could lead to a decision regarding further mitigating measures or changes in risk management strategies. On the other hand, the risk management framework (including the risk management processes) is evaluated by the risk management function, in order to continuously improve the effectiveness of the risk management framework as a whole.

B.3.2 a.s.r.’s risk categories

a.s.r. is exposed to a variety of risks. There are six main risk categories that a.s.r. recognizes, as described below.

Insurance risk

Insurance risk is the risk that premium and/or investment income or outstanding reserves will not be sufficient to cover current or future payment obligations, due to the application of inaccurate technical or other assumptions and principles when developing and pricing products. ASR Basis Ziektekostenverzekeringen N.V. recognizes the following insurance risk:
• Health insurance risk.

Market risk

The risk of changes in values caused by market prices or volatility of market prices differing from their expected values. The following types of market risk are distinguished:
• Interest rate risk;
• Equity risk;
• Property risk;
• Spread risk;
• Currency risk;
• Concentration risk/market concentration risk.

Counterparty default risk

Counterparty default risk is the risk of losses due to the unexpected failure to pay or credit rating downgrade of counterparties and debtors. Counterparty default risk exists in respect of the following counterparties:
• Reinsurers;
• Consumers;
• Intermediaries;
• Counterparties that offer cash facilities;
• Counterparties with which derivatives contracts have been concluded;
• Healthcare providers;
• Zorginstituut Nederland.

Liquidity risk

Liquidity risk is the risk that a.s.r. is not able to meet its financial obligations to policyholders and other creditors when they become due and payable, at a reasonable cost and in a timely manner.

Operational risk

Operational risk is the risk of losses caused by weak or failing internal procedures, weaknesses in the action taken by personnel, weaknesses in systems or because of external events. The following subcategories of operational risk are used:
• Compliance;
• Business process;
• Information technology;
• Outsourcing;
• Financial reporting.

Strategic risk

Strategic risk is the risk of a.s.r. or its business lines failing to achieve the objectives due to incorrect decision-making, incorrect implementation and/or an inadequate response to changes in the environment. Such changes may arise in the following areas:
• Climate;
• Demographics;
• Competitive conditions;
• Technology;
• Macroeconomic conditions;
• Laws and regulations and ethical standards;
• Stakeholders;
• Group structure (for product lines only).

Strategic risk may arise due to a mismatch between two or more of the following components: the objectives (resulting from the strategy), the resources used to achieve the objectives, the quality of implementation, the economic climate and/or the market in which a.s.r. and/or its business lines operate.
B.4 Internal control system

Within a.s.r., internal control is defined as the processes, affected by the board of directors, senior management, and other personnel within the organization, implemented to obtain a reasonable level of certainty with regard to achieving the following objectives:

- High-level goals, aligned with and supporting the organization’s mission;
- Effective and efficient use of resources;
- Reliability of operational and financial reporting;
- Compliance with applicable laws regulations and ethical standards;
- Safeguarding of company assets.

B.4.1 Strategic and operational risk management

The system of internal control includes the management of risks at different levels in the organization, both operational and strategic. Internal control at an operational level centres around identifying and managing risks within the critical processes that pose a threat to the achievement of the business line’s objectives. The use of controls helps to mitigate or even completely eliminate identified risks. This increases the business line’s chances of achieving its objectives and demonstrates that it is in control. Business lines report on the effectiveness of their controls on a quarterly basis. The effectivity of controls is important input for the sign off that each business line provides on the financial figures.

Through a combined top-down and bottom-up SRA (Strategic Risk Analysis) approach, the most important strategic risks are identified. After the analysis a list of risk priorities is established and risk management actions are assigned. The progress of these actions is monitored in the a.s.r. Risk Committee.

B.4.1.1 Strategic Risk Management

Strategic risk management aims to identify and manage the most significant risks that may impact a.s.r.’s strategic objectives. Subsequently, the aim is to identify and analyse the risk profile as a whole, including risk interdependencies. The ORSA process is designed to identify, measure, manage and evaluate those risks that are of strategic importance to a.s.r.:

Identifying

Through the ORSA process, identification of risks is structurally organized through the combined top-down and bottom-up SRA approach. The SRA outcomes are jointly translated into risk scenarios and ‘risk priorities’, in which the most significant risks for a.s.r. are represented.

Measuring

Through the ORSA process, the likelihood and impact of the identified risks are assessed, taking into account (the effectiveness of) risk mitigating measures and planned improvement actions. Information from other processes is used to gain additional insights into the likelihood and impact. One single risk scenario takes multiple risks into account. In this manner, the risk scenarios provide (further) insights into risk interdependencies.

Managing

As part of the SRA processes, the effectiveness of risk mitigating measures and planned measures of improvement is assessed. This means risk management strategies are discussed, resulting in refined risk management strategies.

Monitoring and reporting

The output of the ORSA process is translated into day-to-day risk management and monitoring and reporting, both at group level and product line levels. At group level, the risk priorities are discussed on a quarterly basis in the a.s.r. Risk Committee. At the level of the product lines, risks are discussed in the Business Risk Committees.

Evaluating

Insights regarding likelihood and impact are evaluated against solvency targets. Based on this evaluation, conclusions are formulated regarding the adequacy of solvency objectives at group and individual legal entity level.

B.4.1.2 Operational Risk Management

Operational Risk Management (ORM) involves the management of all possible risks that may influence the achievement of the business goals and that can cause financial or reputational damage. ORM includes the identification, analysis, prioritization and management of these risks in line with the risk appetite. The policy on ORM is drafted and periodically evaluated under the coordination of Enterprise Risk Management. The policy is implemented in the decentralized business entities under the responsibility of the management boards. A variety of risks is covered by ORM policy: IT risk, outsourcing, data quality, underwriting etc.

Identifying

With the operational targets as a starting point, each business entity performs risk assessments to identify events that could influence these targets. In each business entity the business risk manager facilitates the periodic identification of the key operational risks. All business processes are taken into account to identify the risks. All identified risks are prioritized and recorded in a risk-control framework.

---

4 For example, the SAA-study, analyses in the context of reinsurance renewals, ad hoc sensitivity analyses and/or stress tests.
The risk policies prescribe specific risk analyses to be performed to identify and analyse the risks. For important IT systems, SPRINT (Simplified Process for Risk Identification) analyses have to be performed and for large outsourcing projects a specific risk analysis is required.

Measuring
All risks in the risk-control frameworks are assessed on likelihood of defaults and impact. Where applicable, the variables are quantified, but often judgments of subject matter experts are required. Based on the estimation of the variables, each risk is labelled with a specific level of concern (1 to 4). Risks with a level of concern 3 or 4 are considered ‘key’.

Managing
For each risk, identified controls are implemented into the processes to keep the level of risk within the agreed risk appetite (level of concern 1 or 2). In general, risks can be accepted, mitigated, avoided or transferred. A large range of options is available to mitigate operational risks, depending on the type. For each control an estimation is made of the net risk, after implementing the control(s).

Monitoring and reporting
The effectiveness of operational risk management is periodically monitored by the business risk manager at each business line or legal entity. For each key control in the risk-control framework a testing calendar is established, based on accounting standards. Each control is tested regularly and the outcomes of the effectiveness of the management of key risks are reported to the management board. Outcomes are also reported to the NFRC and a.s.r. RC.

Evaluating
Periodically, yet at least annually, the risk-control frameworks and ORM policies are evaluated to see if revisions are necessary. The risk management function also challenges the business lines and legal entities regarding their risk-control frameworks.

Operational incidents
Large operational incidents are reported to Group Risk Management, in accordance with the operational risk policy. The causes of losses are evaluated in order to learn from these experiences. An overview of the largest operational incidents and the level of operational losses is reported to the NFRC. Actions are defined and implemented to avoid repetition of operational losses.

ICT
Through IT risk management, a.s.r. devotes attention to the efficiency, effectiveness and integrity of ICT, including End User Computing applications. The logical access control for key applications used in the financial reporting process remains a high priority in order to enhance the integrity of applications of data. The logical access control procedures also prevent fraud by improving segregation of duties and by conducting regular checks of actual access levels within the applications. Proper understanding of information, security and cyber risks is essential, reason for which continuous actions are carried out to create awareness among employees and business lines.

Business Continuity Management
Operational management can be disrupted significantly by unforeseen circumstances or calamities which could ultimately disrupt the execution of critical and operational processes. Business Continuity Management enables a.s.r. to continue its daily business uninterruptedly and to react quickly and effectively during such situations.

Critical processes and activities and the tools necessary to use for these processes are identified during the Business Impact Analysis. This includes the resources required to establish similar activities at a remote location. The factors that can threaten the availability of those tools necessary for the critical processes are identified in the Threat Analysis.

a.s.r. considers something a crisis when one or more business lines are (in danger of being) disrupted in the operational management, due to a calamity, or when there is a reputational threat. In order to reduce the impact of the crisis, to stabilize the crisis, and to be able to react timely, efficiently and effectively, a.s.r. has assigned a crisis organization.

Each business line has their own crisis team led by the director of the management team. The continuity of activities and the recovery systems supporting critical activities are regularly tested and crisis teams are trained annually. The objective of the training is to give the teams insights into how they function during emergencies and to help them perform their duties more effectively during such situations. The training also sets out to clarify the roles, duties and responsibilities of the crisis teams. One important training scenario used is a scenario that includes cyber threats.

Recovery Planning
a.s.r.’s Recovery Plan helps to be prepared and have the capacity to act in various forms of extreme financial stress. The Recovery Plan describes and quantifies the measures that can be applied to live through a crisis situation. These measures are tested in the scenario analysis, in which the effects of each recovery measure on a.s.r.’s financial position (solvency and liquidity) are quantified. The required preparations for implementing the measures, their implementation time and effectiveness, potential obstacles and operational effects are also assessed. The main purpose of the Recovery Plan is to increase the chances of successful early intervention in the event of a financial crisis situation and to further guarantee that the interest of policyholders and other stakeholders are protected.
Reasonable assurance and model validation
a.s.r aims to obtain reasonable assurance regarding the adequacy and accuracy of the outcomes of models that are used to provide best estimate values and solvency capital requirements. To this end, multiple instruments are applied, including model validation. Materiality is determined by means of an assessment of impact and complexity. Impact and complexity is expressed in terms of High (H), Medium (M), or Low (L).

In the pursuit of reasonable assurance, model risk is mitigated and unpleasant surprises are avoided, against acceptable costs.

B.4.2 Compliance function

The mission of the compliance function is to enhance and ensure a controlled and sound business operation in which impeccable, professional conduct is self-evident.

Positioning and structure of the compliance function
The compliance function is a centralised function which is headed by the a.s.r. Compliance Officer for both a.s.r. and the supervised entities. The compliance function, the second line of defence, is considered a key function in line with the Solvency II regulation. The CEO bears ultimate responsibility for the compliance function and the a.s.r. Compliance Officer has direct access to him. The a.s.r. Compliance Officer also has an escalation line to the Chairman of the a.s.r. Audit & Risk Committee and/or the Chairman of the Supervisory Board in order to safeguard the independent position of the compliance function and enables it to operate autonomously. The a.s.r. Compliance Officer is entitled to upscale critical compliance matters to the highest organisational level or to the Supervisory Board.

Responsibilities and duties
The compliance function, as part of the second line of defence, is responsible for:
- Encouraging compliance with relevant rules and regulations, ethical standards and the internal standards derived from them (‘rules’) by providing advice and formulating policies;
- Monitoring compliance with rules;
- Monitoring the management of compliance risks by developing adequate compliance risk management, including monitoring and, where necessary, making arrangements relating to proposed management actions;
- Creating awareness of the need to comply with rules and of social and ethical issues, in which context ethical behaviour within a.s.r. is self-evident;
- Coordinating contacts with regulators in order to maintain effective and transparent relationships with them.

Annual compliance plan
Developments in rules and the management of high compliance risks and action plans provide the basis for the annual compliance plans and the compliance monitoring activities. a.s.r. continuously monitors changing legislation and regulations and assesses the impact and corresponding actions to be taken. In 2018, a.s.r. paid specific attention to:
- General Data Protection Regulation (GDPR): The Privacy Officer falls under Compliance and was a member of the GDPR central project group. Compliance advises on privacy issues and monitors compliance with relevant legislation and regulations as a second line of defence;
- Insurance Distribution Directive (IDD): Compliance was part of both centralised and decentralised projects to implement IDD as from 1 October 2018.

Based on the annual plan, Compliance monitors every year the compliance of rules. In 2018, Compliance conducted a.s.r.-wide monitoring surveys on compliance with the sanction regulations and CDD policy, privacy and the quality of customer contacts and underlying procedures. The findings have been reported to and discussed with responsible management, the a.s.r. Risk Committee and the Audit & Risk Committee. Actions have been taken with regard to unify processes and training of employees.

Reporting
The compliance function reports on compliance matters and progress made on the relevant actions at Group level, supervised entity level and division level on a quarterly basis. The quarterly report at division level is discussed with the responsible management and scheduled for discussion by the Business Risk Committee.

The quarterly report at Group level and supervised entity level is presented to and discussed with the a.s.r. Risk Committee and submitted to the Audit & Risk Committee. The report is shared and discussed with the DNB, the AFM and the external auditor.

B.5 Internal audit function

This paragraph contains a description of group policy, which is applicable for ASR Basis Ziektekostenverzekeringen N.V. The Audit Department provides a professional and independent assessment of the governance, risk management and internal control processes with the aim of aiding management in achieving the company’s objectives. This statement of duties has been set down in the Audit Charter for ASR Nederland N.V. and its subsidiaries. The Audit Department reports its findings to the managing board of ASR Basis Ziektekostenverzekeringen N.V. and, by means of the quarterly management report, to the Supervisory Board of ASR Basis Ziektekostenverzekeringen N.V.

The Audit Department has an independent position within a.s.r., as set down in the Audit Charter. The Supervisory Board of ASR Nederland N.V. guarantees Audit and its employees an independent, impartial and autonomous
position in order to execute the mission of Audit. The head of the Audit Department reports to the chairman of the Executive Board of ASR Nederland N.V. and has a reporting line to the chairman of the Supervisory Board of ASR Basis Ziektekostenverzekeringen N.V. and to the chairman of the a.s.r. Audit and Risk Committee. The Chief Audit Executive is appointed by the supervisory board of ASR Nederland N.V. In order to maintain the independence and impartiality of the internal audit function, the audit function is not influenced by the Executive Board of ASR Nederland N.V. and the managing board of ASR Basis Ziektekostenverzekeringen N.V. in the execution of an audit and the evaluation of and reporting on audit outcomes. The audit function is not subjected to any inappropriate influence from any other function, including the key functions.

The persons carrying out the internal audit function do not assume any responsibility for any other (key) function. The Audit Department has periodic consultations with DNB to discuss the risk assessment, findings and audit plan. The department also takes the initiative to organize a ‘tripartite consultation’ with DNB and the independent external auditor at least once a year. In 2018, one tripartite consultation was held for ASR Basis Ziektekostenverzekeringen N.V.

The Audit Department sets up a multi-year audit plan based upon an extensive risk assessment. The Audit Department’s risk assessment is performed in consultation with the independent external auditor. The audit plan is approved by the a.s.r. Audit and Risk Committee. At least once a year, the audit plan is evaluated and any changes to the plan must be approved by the a.s.r. Audit and Risk Committee.

All Audit officers took the oath for the financial sector and are subject to disciplinary proceedings. All Audit officers have committed themselves to the applicable code of conduct of a.s.r., follow the Code of Ethics of the Institute of Internal Auditors (IIA) and comply with the specific professional rules of the Netherlands Institute of Chartered Accountants (NBA) and the professional association for IT-auditors in the Netherlands (NOREA).

Audit applies the standards of the IIA, NBA and NOREA for the profession of internal auditing. Each year, Audit performs a self-assessment and an internal quality review and reports the results to the chairman of the board and to the members of the a.s.r. Audit and Risk Committee. In accordance with the standards of the IIA, an external quality review is performed every five years. During the last review in 2016, Audit was approved by the IIA and received the Institute’s quality certificate.

B.6 Actuarial function

This paragraph contains a description of group policy, which is applicable for ASR Basis Ziektekostenverzekeringen N.V. The Actuarial Function (AF) is one of four key functions in a.s.r.’s system of governance.

The main tasks and responsibilities of the AF are to:
• Coordinate the calculation of technical provisions;
• Ensure the appropriateness of the methodologies, underlying models and the assumptions made in the calculation of technical provisions;
• Assess the sufficiency and quality of the data used in the calculation of technical provisions;
• Compare best estimates against experience;
• Inform the administrative, management or supervisory body of the reliability and adequacy of the calculation of technical provisions;
• Express an opinion on the adequacy of reinsurance arrangements; and
• Contribute to the effective implementation of the risk management system.

The AF is part of the second line of defense and operates independently of both the first line (responsible for determining the technical provisions, reinsurance and underwriting), as well as the other three key functions (internal audit, risk management and compliance).

The AF for both ASR Nederland N.V. and the insurance legal entities is operationally part of a.s.r. Group Risk Management. The AF is performed by persons who have profound knowledge of actuarial and financial mathematics, proportionate to the nature, scale and complexity of the risks present in a.s.r.’s businesses.

There are two function holders. One is responsible for the legal entities in the Life segment (Individual Life, Funeral and Pensions business lines) as well as for the overall Life segment of ASR Nederland N.V. The other for the entities in the Non-life segment (Property & Casualty, Disability and Health business lines) as well as for the overall Non-life segment of ASR Nederland N.V.

The AF function is represented in several risk committees. Each year, the AF drafts a formal report, which it discusses with the a.s.r. Risk Committee (or Executive Board) and the a.s.r. Audit & Risk Committee.
Independence of the AF is secured through several measures:

• The Actuarial function holders are appointed and dismissed by the Board. Both the appointment and the dismissal of the holders is, together with an advice from the Audit and Risk Committee, submitted to the Supervisory Board for approval;

• The Actuarial function holders have unrestricted access to all relevant information necessary for the exercise of their function;

• The Actuarial function holders have a direct reporting line to the a.s.r. Risk Committee or Executive Board and the Audit and Risk Committee of a.s.r. The AF is free to report to one of the management or risk committees when considered necessary;

• The AF is free to report all relevant issues;

• In case of a conflict of interest with the CFO and/or CRO, the function holders may escalate directly to the CEO and to the Chairperson of the Audit & Risk Committee of a.s.r.;

• If the AF is asked to perform tasks that are outside the formal scope described in a charter, the function holder(s) assess if there is a conflict of interest. If so, the AF will not execute the task unless there are sufficient additional measures to mitigate conflicts of interest;

• The Internal Audit Department conducts an annual assessment of the functioning of the governance of a.s.r. including the (independent) operation of the Actuarial function;

• Target Setting and assessment of the function holders is done by the CFO and must be approved by the Chairman of the Audit & Risk Committee.

B.7 Outsourcing

This paragraph contains a description of group policy, which is applicable for the solo entity ASR Basis Ziektekostenverzekeringen N.V. as well. a.s.r. has outsourced some of its operational activities. Despite this, a.s.r. remains fully responsible and accountable for these activities and the power of influence remains with a.s.r. To manage the risks related to outsourcing, a.s.r. has drafted a policy to safeguard a controlled and sound business operations.

Solid risk management, governance and monitoring are essential to manage outsourced activities. The outsourcing policy outlines the relevant procedures and is applicable to a.s.r. and its subsidiaries. To define the respective rights and obligations, a.s.r. drafts a written outsourcing contract with the service provider. Confidentiality, quality of service and continuity are key for a.s.r. in carrying out its activities. In addition, customer centricity and compliance with law and regulations are essential, regardless of who performs the activities. To safeguard the quality of outsourced activities, service providers are closely scrutinized prior to selection and during the services. Compliance with agreed obligations is monitored. The findings of the monitoring activities serve as input for the periodic consultation on operational, tactical and strategic level with the service provider.

B.8 Any other information

Other material information about the system of governance does not apply.
Risk profile

This paragraph contains a description of group policy, which is applicable for the solo entity. Risk management is an integral part of a.s.r.’s daily business operations. a.s.r. applies an integrated approach to managing risks ensuring that strategic objectives are met. Value is created by striking the right balance between risk and return and capital, whilst ensuring that obligations to stakeholders are met. The Risk Management Function (RMF) supports and advises a.s.r. in identifying, measuring and managing risks, and ensures that adequate and immediate action is taken in the event of developments in the risk profile.

a.s.r. is exposed to a number of risks, such as strategic risks, market risks, counterparty default risks, liquidity risks, underwriting risks. The RMF monitors the risk profile of a.s.r. and its legal entities in order to ensure that it stays within the risk appetite.

As of 1 January 2016, the Solvency II regime is in place. a.s.r. measures its risks based on the standard model as prescribed by the Solvency II regime and therefore the risk management framework and this chapter are fully aligned with Solvency II. The Solvency Capital Requirement (SCR) is determined as the change in own funds caused by a predetermined shock which is calibrated to a 1-in-200-year event. The basis for these calculations are the Solvency II technical provisions which are calculated as the sum of a best estimate and a risk margin.

Management of financial risks in 2018
a.s.r. strives for an optimal trade-off between capital, risk and return. Steering on capital, risk and return is applied in decision-making throughout the entire product cycle: from PARP (Product Approval Review Process) to the payment of benefits and claims. At a more strategic level, decision-making takes place through balance sheet management. A robust solvency position takes precedence over profit, premium income and direct investment income. Risk tolerance levels and limits are disclosed in the financial risk appetite statements (financial RAS) and are monitored by the FRC. The FRC evaluates financial risk positions against the RAS on a monthly basis. Where appropriate, a.s.r. takes additional mitigating measures.

In 2018 the Actuarial Function performed its regulatory tasks in assessing the adequacy of the Solvency II technical provisions, giving an opinion on reinsurance and underwriting and contributing to the Risk Management Function. The actuarial function report relating to these areas was discussed by the Executive Board and by the Audit & Risk Committee.

Management of non-financial risks in 2018
Non-financial risk appetite statements are in place to manage the risk profile within the limits determined by the Executive Board and approved by the Supervisory Board. The Non-Financial Risk Committee (NFRC) monitors and discusses on a quarterly basis whether non-financial risks are adequately managed. Should the risk profile exceed the risk appetite, the NFRC will decide on actions to be taken. The financial and non-financial risk profiles are integrated on behalf of the a.s.r. Risk Committee. In the event of breaches, the a.s.r. Risk Committee is authorised to decide on corrective actions. The risk profile and internal control performance of each business is discussed on a quarterly basis with senior management in the business risk committees and the NFRC.

In 2018, a.s.r. took steps to further improve the effectiveness of the Risk Management Function. The Operational Risk Management (ORM) policy including underlying procedures is updated towards a more risk based approach. Tasks and responsibilities of the first and second line (including the role of assessor by the RMF) of defense are tightened in the ORM policy and underlying procedures.

In order to enhance the uniformity, efficiency and effectiveness of the risk- and control cycle, a.s.r. additionally purchased and rolled-out the Governance and Risk Compliance (GRC) tool (‘Cerrix’). ASR Basis Ziektekostenverzekeringen N.V. makes use of this tool and will continue the roll-out of the tool throughout the organisation with new modules to further improve the implementation of the operational risk management policies. ASR Basis Ziektekostenverzekeringen N.V. will naturally continue to look for opportunities to improve the management of its operational risks in 2019.

In 2018, a.s.r. took various actions to enhance the measurement and reporting of data quality for financial reporting purposes and to mitigate the end-user computing risks. A project to address these items has started in the beginning of 2018 and is expected to be completed in the beginning of 2019.

Risk priorities 2018
The strategic risks of ASR Basis Ziektekostenverzekeringen N.V. are annually defined by the Board based on the Strategic Risk Analysis. The most recent status of the risk priorities and progress on the defined actions are reported to the a.s.r. Non-Financial Risk Committee quarterly.
The strategic risks are:
1. Higher than market average risk of incurred losses (LoC 3)
2. Non-competitive premium as a result of (direct and recharged costs) organization costs (LoC 3)
3. Less solvability than internal standard (130%) (LoC 4)
4. Information (cyber) security risk (LoC 3)

To determine the degree of risk, a.s.r. uses a risk scale based on likelihood and impact (Level of Concern). For the risk priorities, the degree of risk is determined by the a.s.r. Risk Committee quarterly. The following table shows the degree of risk per 2018Q4.

**Degree of risk per 2018Q4**

<table>
<thead>
<tr>
<th>Likelihood</th>
<th>LoC 1: low degree of risk (inside risk appetite boundaries)</th>
<th>LoC 2: acceptable degree of risk (inside risk appetite boundaries)</th>
<th>LoC 3: high degree of risk (outside risk appetite boundaries)</th>
<th>LoC 4: very high degree of risk (outside risk appetite boundaries)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gross risk</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>Impact</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net risk</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Likelihood</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Gross risk: the risk that exists if there are no (control) measures in place to mitigate the risk. Net risk: risk when taking into account a.s.r.’s mitigating measures.

**Higher than market average risk of incurred losses**

There is a trend that risks are increasingly placed with health insurers, leading to volatility of incurred losses that cannot be accounted for in (competitive) premiums and which therefore have to be retrieved from the company’s own equity. This can result in solvability decline and other financial consequences.

**Non-competitive premium as a result of organization costs**

A smaller portfolio in an increasingly price sensitive market can prompt diseconomies of scale when spreading operational costs, resulting in a non-competitive premium.

**Lower solvability than internal standard (130%)**

In case of a higher than expected increase of incurred losses and/or the organization costs, there is a possibility the SCR will decrease to or below the internal standard of 130% and a growth strategy will be impossible. In its capital policy, a.s.r. has listed several measures to deal with this risk.

**Information (cyber) security risk**

By virtue of cyber threats (loss of confidential information, CEO-fraud, phishing, social engineering, ransomware and DDoS-attacks); misuse of vulnerabilities (security flaws in software); user mistakes; IT disruptions; and power- and internet outs, there is the possibility of information theft or manipulation and damaged integrity of information processing and systems, leading to financial and reputation damage.

a.s.r. takes measures to mitigate risks outside the risk appetite boundaries.

**Solvency II sensitivities**

The sensitivities of the solvency ratio as at 31 December 2018, expressed as the impact on the ASR Basis Ziektekostenverzekeringen N.V. solvency ratio (in percentage points) are as presented in the table below. The total impact is split between the impact on the solvency ratio related to movement in the available capital and the required capital.
### Solvency II sensitivities - market risks

<table>
<thead>
<tr>
<th>Scenario (%-point)</th>
<th>Available capital</th>
<th>Required capital</th>
<th>Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>31 December 2018</td>
<td>31 December 2017</td>
<td></td>
</tr>
<tr>
<td>UFR 3.2%</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Interest rate +1% (2017 incl. UFR 4.2% / 2018 incl. UFR 4.05%)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Interest rate -1% (2017 incl. UFR 4.2% / 2018 incl. UFR 4.05%)</td>
<td>-</td>
<td>+1</td>
<td>-</td>
</tr>
<tr>
<td>Volatility Adjustment -10bp</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Spread +75bps/VA +20/21bps</td>
<td>-1</td>
<td>-2</td>
<td>-1</td>
</tr>
</tbody>
</table>

### Solvency II sensitivities - explanation

**Risk** | **Scenario**
---|---
Interest rate risk – UFR | Measured as the impact of a lower UFR. For the valuation of liabilities, the extrapolation to the UFR of 3.2% after the last liquid point of 20 years remained unchanged.
Interest rate risk (incl. UFR 4.05%) | Measured as the impact of a parallel 1% upward and downward movement of the interest rates. For the liabilities, the extrapolation to the UFR of 4.05% after the last liquid point of 20 years remained unchanged.
Volatility Adjustment | Measured as the impact of a 10 bps decrease in the Volatility Adjustment.
Spread risk (including impact of spread movement on VA) | Measured as the impact of an increase of spread on loans and corporate bonds of 75 bps. At the same time, it is assumed that the Volatility Adjustment will increase by 20bps (2017 was 21 bps) based on reference portfolio.

The Solvency II sensitivities in 2018 are almost similar to 2017. Furthermore, the magnitude of the Solvency II sensitivities is small, as the insurances are short-cycle.

### Expected development UFR

European Insurance and Occupational Pensions Authority (EIOPA) may reduce the ultimate forward rate used to extrapolate insurers’ discount curves to better reflect expected inflation and real interest rates. There are various scenarios regarding lowering the Ultimate Forward Rate (UFR).

The UFR will decrease, starting 2018, from 4.2% to 3.6% with steps of 15 basis points per year. In 2018 the UFR was 4.05%. After the decline of the UFR by 15 basis points the solvency ratio is still above internal solvency objectives.

Changes in the UFR have an almost linear effect on the solvency ratio. The impact on the solvency ratio of various UFR levels is stated below.
The impact of the interest rate on the Solvency II ratio, including the UFR effect, is stated below (the impact is marginal). The UFR methodology has been applied to the shocked interest rate curve.

### Spread risk
In 2017 ASR Basis Ziektekostenverzekeringen N.V. the fixed income portfolio decreased, including corporates and financials. As a result, the required capital for spread risk decreased.

In case of a scenario in which the average spread rises by 75 bps and the Volatility Adjustment (VA) rises by 21 bps, the solvency ratio decreases -2%. As the VA is used in the calculation of the liabilities and spread movement only has an impact on the credit portfolio, the impact of the VA increase is bigger than the impact of the spread increase. Therefore, the solvency ratio rises in the event of an increase in the average spread.

### Loss absorbing capacity of deferred tax
For ASR Basis Ziektekostenverzekeringen N.V., the LAC DT factor is nil.
C.1 Insurance risk

Insurance risk is the risk that future insurance claims and benefits cannot be covered by premium and/or investment income, or that insurance liabilities are not sufficient, because future expenses, claims and benefits differ from the assumptions used in determining the best estimate liability. The healthcare sector is part of the non-life portfolio.

The solvency buffer is held by ASR Basis Ziektekostenverzekeringen N.V. to cover the risk that claims may exceed the available insurance provisions and to ensure its solidity. The solvency position of ASR Basis Ziektekostenverzekeringen N.V. is determined and continuously monitored in order to assess if ASR Basis Ziektekostenverzekeringen N.V. meets the regulatory requirements.

As of 1 January 2016, the Solvency II regime is in place. ASR Basis Ziektekostenverzekeringen N.V. measures its risks based on the standard model as prescribed by the Solvency II regime. The Solvency Capital Requirement for each insurance risk is determined as the change in own funds caused by a predetermined shock which is calibrated to a 1-in-200-year event. The basis for these calculations are the Solvency II technical provisions which are calculated as the sum of a best estimate and a risk margin.

The insurance risk arising from the health insurance portfolio of ASR Basis Ziektekostenverzekeringen N.V. is as follows.

<table>
<thead>
<tr>
<th>Insurance risk - required capital</th>
<th>31 December 2018</th>
<th>31 December 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Health insurance risk</td>
<td>70,379</td>
<td>68,765</td>
</tr>
</tbody>
</table>

Solvency II sensitivities

a.s.r. has assessed the impact of various sensitivities on the solvency ratio. The sensitivities as at 31 December 2017 and 2018, expressed as impact on the ASR Basis Ziektekostenverzekeringen N.V.’s solvency ratio (in percentage points) are as follows:

<table>
<thead>
<tr>
<th>Solvency II sensitivities - insurance risks</th>
<th>2018</th>
<th>2017</th>
<th>Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type of risk (%) - Points</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pandemic (as of 2018)</td>
<td>-3</td>
<td>-2</td>
<td>-3</td>
</tr>
</tbody>
</table>

Solvency II sensitivities - explanation

Risk Scenario
Pandemic risk Measured as the pandemic scenario defined in the Delegated Regulation

Pandemic risk is only present in ASR Basis Ziektekostenverzekeringen N.V. and not in ASR Aanvullende Ziektekostenverzekeringen N.V., as the claim height is maximized. These maximums are included in the price of the insurance and therefore have no effect on the eventual profit of ASR Aanvullende Ziektekostenverzekeringen N.V. In case of a catastrophic event, claims will be covered by ASR Basis Ziektekostenverzekeringen N.V.

The impact on the ratio is the opposite if a reversed scenario is taken into account. These shocks had no impact on the 2018 and 2017 total equity, or on the profit for these years, because a.s.r. still passed the IFRS Liability Adequacy Test (LAT). While the sensitivities result in a decrease of the surplus in the Liability Adequacy Test, the outcome is still positive.

C.1.1 Health Insurance risk

The Health insurance portfolio of ASR Basis Ziektekostenverzekeringen N.V. contains the following insurance risks:

- NSLT Health insurance risk
  - This risk is applicable to the NSLT Health portfolio. The calculation is factor-based. The risk is calculated similar to the Non-Life insurance risk Solvency II standard model.
- Health Catastrophe risk
  - The calculation of this risk is scenario-based. Below the specific health parameters for the calculation are explained.

This includes the diversification within the NSLT Health underwriting risk and Catastrophe risk. There is a slight change in the Health insurance risk during the year 2018.
NSLT Health Risk

**Premium and reserve risk**
The premium risk is the risk that the premium is not adequate for the underwritten risk. The premium risk is calculated over the maximum of the expected earned premium of the next year, and the earned premium of the current year.

Reserve risk is the risk that the current reserves are insufficient to cover the claims over a 12-month time horizon.

**NSLT lapse risk**
The basic health insurance is a compulsory insurance contract for one year without intermediate possibility of termination during contract year, and therefore lapse risk is negligible for basic health insurance.

---

Health catastrophe risk

**Medical Expense**
A health catastrophe for NSLT Health portfolio is an unexpected future event with a duration of one year. The risk is determined ultimo year. The amount of catastrophe risk is apparent from the number of insured and parameters for mass accident scenario and pandemic scenario that have been approved by Dutch Central Bank in consultation with Health Insurers Netherlands. Accident concentration is not applicable for NSLT Health. The catastrophe risk has a projection of one year (T) following from the contract boundary of one year in accordance with the Dutch Health Insurance Act for Health Insurance. After year T the risk is ‘zero’.

Below table summarizes the required capital for abovementioned life insurance risks based on the standard model. For the life portfolio, the provision at year-end can be broken down as follows under Solvency II:

<table>
<thead>
<tr>
<th>Health portfolio - technical provisions per segment</th>
<th>31 December 2018</th>
<th>31 December 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>in € thousand</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Health SLT</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Health Non-SLT</td>
<td>69,762</td>
<td>68,120</td>
</tr>
<tr>
<td>Catastrophe Risk (subtotal)</td>
<td>2,323</td>
<td>2,418</td>
</tr>
<tr>
<td>Diversification (negative)</td>
<td>-1,706</td>
<td>-1,774</td>
</tr>
<tr>
<td><strong>Health (Total)</strong></td>
<td><strong>70,379</strong></td>
<td><strong>68,765</strong></td>
</tr>
<tr>
<td>Medical expenses insurance and proportional reinsurance</td>
<td>69,762</td>
<td>68,120</td>
</tr>
<tr>
<td>Income protection insurance and proportional reinsurance</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Diversification (negative)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Health SLT (subtotal)</strong></td>
<td><strong>69,762</strong></td>
<td><strong>68,120</strong></td>
</tr>
<tr>
<td>Mass accident risk</td>
<td>166</td>
<td>166</td>
</tr>
<tr>
<td>Accident concentration risk</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Pandemic risk</td>
<td>2,317</td>
<td>2,412</td>
</tr>
<tr>
<td>Diversification (negative)</td>
<td>-160</td>
<td>-160</td>
</tr>
<tr>
<td><strong>Catastrophe risk (subtotal)</strong></td>
<td><strong>2,323</strong></td>
<td><strong>2,418</strong></td>
</tr>
</tbody>
</table>

For the NSLT Health portfolio, the technical provision at year-end can be broken down as follows under Solvency II:

<table>
<thead>
<tr>
<th>NSLT Health portfolio - technical provision</th>
<th>31 December 2018</th>
<th>31 December 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>in € thousand</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Best estimate</td>
<td>184,259</td>
<td>189,007</td>
</tr>
<tr>
<td>Risk margin</td>
<td>7,776</td>
<td>7,856</td>
</tr>
<tr>
<td><strong>Technical provision</strong></td>
<td><strong>192,035</strong></td>
<td><strong>196,863</strong></td>
</tr>
</tbody>
</table>

The table above shows a stable pattern of the best estimate.
C.1.2 Managing health insurance risk

Health insurance risk is managed by monitoring claims frequency, the size of claims, inflation, handling time, benefit and claims handling costs. Concentration risk also qualifies as an insurance risk.

Claims frequency, size of claim and inflation
To mitigate the risk of claims, ASR Basis Ziektekostenverzekeringen N.V. bases its underwriting policy on claims history and risk models. The policy is applied to each client segment and to each type of activity. In order to limit claims and/or ensure that prices are adjusted correctly, the product line health NSLT also uses knowledge or expectations with respect to future trends to estimate the frequency, size and inflation of claims.

Another mitigation of risks is performed by including in almost all of the contractual agreements with a health institution a maximum of claims amount. The health institution is allowed to invoice their claims until the maximum is reached. If the claims exceed the maximum, a.s.r. can retrieve the amount above the maximum. This amount is called revenue settlement. By using this method, the individual risk (claims) per health institution can be monitored and managed.

Handling time
The handling time for health care claims is mainly very short and the settlement is quick. Normally, within five days a claim is settled.

Benefit and claims handling costs
Taking estimated future inflation into account, benefit and claims handling costs are managed based on regular reviews and related actions.

C.2 Market risk

Market risk is the risk of potential losses due to adverse movements in financial market variables. Exposure to market risk is measured by the impact of movements in financial variables such as equity prices, interest rates and property prices. The various types of market risk which are discussed in this section, are:

- Interest rate risk;
- Equity risk;
- Property risk;
- Currency risk;
- Spread risk;
- Concentration risk.

Market risk reports are submitted to the FRC at least once a month. Key reports on market risk include the Solvency II and economic capital report, the interest rate risk report and the report on risk budgets related to the strategic asset mix.

A summary of sensitivities to market risks for the regulatory solvency, total equity and profit for the year is presented in the tables below. The first table summarizes the required capital for market risks based on the standard model:

<table>
<thead>
<tr>
<th>Market risk - required capital</th>
<th>31 December 2018</th>
<th>31 December 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interest rate</td>
<td>187</td>
<td>729</td>
</tr>
<tr>
<td>Equity</td>
<td>87</td>
<td>98</td>
</tr>
<tr>
<td>Property</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Currency</td>
<td>56</td>
<td>163</td>
</tr>
<tr>
<td>Spread</td>
<td>7,136</td>
<td>7,454</td>
</tr>
<tr>
<td>Concentration</td>
<td>364</td>
<td>416</td>
</tr>
<tr>
<td>Diversification (negative)</td>
<td>-603</td>
<td>-1,240</td>
</tr>
<tr>
<td>Total</td>
<td>7,228</td>
<td>7,620</td>
</tr>
</tbody>
</table>

The main market risk of ASR Basis Ziektekostenverzekeringen N.V. is spread risk. This is in line with the risk budgets based on the strategic asset allocation study.

The interest rate risk is the maximum loss of (i) an upward shock or (ii) a downward shock of the yield curve. For ASR Basis Ziektekostenverzekeringen N.V. the upward shock is dominant.

ASR Basis Ziektekostenverzekeringen N.V. applies the transitional measure for equity risk for shares in portfolio at 31 December 2015. The SCR equity shock was 22% at 31 December 2015 and linear, increasing to (i) 39% + equity.
dampener for type I shares and (ii) 49% + equity dampener for type II shares. The equity dampener has a value between -10% and 10%. In the event of increasing equity prices, the equity dampener will have a smaller dampening effect.

The diversification effect shows the effect of having a diversified investment portfolio.

C.2.1 Interest rate risk

Interest rate risk is the risk that the value of assets, liabilities or financial instruments will change due to fluctuations in interest rates. Many insurance products are exposed to interest rate risk; the value of the products is closely related to the applicable interest rate curve. The interest rate risk of insurance products depends on the term to maturity, interest rate guarantees and profit-sharing features. Life insurance contracts are particularly sensitive to interest rate risk. The required capital for interest rate risk is determined by calculating the impact on the available capital due to changes in the yield curve. Both assets and liabilities are taken into account. The interest rate risk is the maximum loss of (i) an upward shock or (ii) a downward shock of the yield curve according to the prescribed methodology. a.s.r. applies a look-through approach for investment funds to assess the interest rate risk.

The interest rate risk is calculated by a relative shock upward and downward shock of the risk-free (basis) yield curve. All adjustments (credit spread, volatility adjustment) on this yield curve are considered constant. The yield curve is extrapolated to the UFR. The yield curve after shock is not extrapolated again to the UFR.

The used shocks vary by maturity and the absolute shocks are higher for shorter maturities (descending: 75% to 20% and ascending: -70% to -20%):

- The yield curve up shock contains a minimum shock of 100bps;
- The yield curve after the downward shock is limited to zero (no negative interest rates);
- The yield curves of all currencies are shocked simultaneously.

<table>
<thead>
<tr>
<th>Interest rate risk - required capital</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCR interest rate risk up</td>
</tr>
<tr>
<td>SCR interest rate risk down</td>
</tr>
<tr>
<td><strong>SCR interest rate risk</strong></td>
</tr>
</tbody>
</table>

A.S.R. Basis Ziektekostenverzekeringen N.V. has assessed various scenarios to determine the sensitivity to interest rate risk. The impact on the solvency ratio is calculated by determining the difference in the change in available and required capital.

<table>
<thead>
<tr>
<th>Solvency II sensitivities - interest rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Effect on:</td>
</tr>
<tr>
<td>Scenario (%-point)</td>
</tr>
<tr>
<td>UFR 3.2%</td>
</tr>
<tr>
<td>Interest rate +1% (2017 incl. UFR 4.2% / 2018 incl. UFR 4.05%)</td>
</tr>
<tr>
<td>Interest rate -1% (2017 incl. UFR 4.2% / 2018 incl. UFR 4.05%)</td>
</tr>
<tr>
<td>Volatility Adjustment -10bp</td>
</tr>
</tbody>
</table>

Interest rate risk is managed by aligning fixed-income investments to the profile of the liabilities. Among other instruments, swaptions and interest rate swaps are used for hedging the specific interest rate risk arising from interest rate guarantees and profit-sharing features in life insurance products.

An interest rate risk policy is in place for the Group as well as for the registered insurance companies. All interest rate-sensitive balance sheet items are in scope, including the employee benefit obligations of the Group. In principle, the sensitivity of the solvency ratio to interest rates is minimized. In addition, the exposure to interest rate risk or various term buckets is subject to maximum amounts.

C.2.2 Equity risk

The equity risk depends on the total exposure to equities. In order to maintain a good understanding of the actual equity risk, a.s.r. applies the look-through approach for investment funds to assess the equity risk. The required capital for equity risk is determined by calculating the impact on the available capital due to an immediate drop in share prices. Both assets and liabilities are taken into account. Stocks listed in regulated markets in countries in the EEA or OECD are shocked by 39% together with the symmetric adjustment of the equity capital charge (type I). Stocks in countries that are not members of the EEA or OECD, unlisted quities, alternative investments, or investment funds in which the look-through principle is not
possible, are shocked by 49% together with the symmetric adjustment of the equity capital charge (type II).
a.s.r. Basis Ziektekostenverzekeringen N.V. applies the transitional measure for equity risk for shares in portfolio at 31 December 2015. The SCR equity shock was 22% at 31 December 2015 and linear increasing in 7 years to (i) 39% + equity dampener for type I shares and (ii) 49% + equity dampener for type II shares.

<table>
<thead>
<tr>
<th>Equity risk - required capital</th>
</tr>
</thead>
<tbody>
<tr>
<td>31 December 2018</td>
</tr>
<tr>
<td>SCR equity risk - required capital</td>
</tr>
</tbody>
</table>

The equity risk is very limited and the result of a forced conversion.

<table>
<thead>
<tr>
<th>Solvency II sensitivities - equity prices</th>
</tr>
</thead>
<tbody>
<tr>
<td>Effect on: Available capital Required capital Ratio</td>
</tr>
<tr>
<td>Scenario (%-point)</td>
</tr>
<tr>
<td>Equity prices -20%</td>
</tr>
</tbody>
</table>

Composition of equity portfolio
The fair value of equities and similar investments at year-end 2018 was € 0.2 million (2017: € 0.2 million). ASR Ziektekosten Basis doesn’t invest in equities. The current exposure to equity risk is the result of an forced conversion.

<table>
<thead>
<tr>
<th>Composition equity portfolio</th>
</tr>
</thead>
<tbody>
<tr>
<td>31 December 2018</td>
</tr>
<tr>
<td>Mature Markets (euro)</td>
</tr>
<tr>
<td>Dutch Participations</td>
</tr>
<tr>
<td>Alternatives</td>
</tr>
<tr>
<td>Emerging Markets</td>
</tr>
<tr>
<td>Mature Markets (non-euro)</td>
</tr>
<tr>
<td>Equity Options</td>
</tr>
<tr>
<td>Other</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>

C.2.3 Property risk
Property risk is not applicable for ASR Basis Ziektekostenverzekeringen N.V.

C.2.4 Currency risk
Currency risk measures the impact of losses related to changes in currency exchange rates. The table below provides an overview of all currencies with exposure on liabilities and the currencies with the largest exposures. The policy of a.s.r. is in principle to hedge the currency risk excluding investments in equities and investments that are externally managed. However, certain currency exposures are permitted from a tactical perspective within a specific risk budget.

The required capital for currency risk is determined by calculating the impact on the available capital due to a change in exchange rates. Both assets and liabilities are taken into account and a look-through approach is applied for investment funds. For each currency the maximum loss due to an upward and a downward shock of 25% is determined except for a small number of currencies where lower shocks are applied (Danish crown, Bulgarian lev).
Currency risk - required capital

<table>
<thead>
<tr>
<th>SCR currency risk - required capital</th>
<th>31 December 2018</th>
<th>31 December 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>56</td>
<td>163</td>
</tr>
</tbody>
</table>

Currency risk has decreased 107 thousand. This is caused by a decrease in foreign bonds.

Specification currencies with largest exposure
Foreign bonds have substantially decreased in the following currencies: USD and GBP. The USD bonds have a negative value, which results in a negative net exposure, as a result the exposure for 2018 is above 100%. This is against the hedge policy of a.s.r. and therefore this is resolved as per January 2019 by increasing the asset exposure of a.s.r.

Composition currency portfolio

![Composition Currency Portfolio 2018](image1)

![Composition Currency Portfolio 2017](image2)

C.2.5 Spread risk
Spread risk arises from the sensitivity of the value of assets and liabilities to changes in the level of credit spreads on the relevant risk-free interest rates. a.s.r. has a policy of maintaining a well-diversified high-quality investment grade portfolio while avoiding large risk concentrations. Going forward, the volatility in spreads will continue to have possible short-term effects on the market value of the fixed income portfolio. In the long run, the credit spreads are expected to be realized and to contribute to the growth of the own funds. The required capital for spread risk is determined by calculating the impact on the available capital due to the volatility of credit spreads over the term structure of the risk-free rate.

The required capital for spread risk is equal to the sum of the capital requirements for bonds, structured products and credit derivatives. The capital requirement depends on (i) the market value, (ii) the modified duration and (iii) the credit quality category.

Spread risk - required capital

<table>
<thead>
<tr>
<th>SCR spread risk - required capital</th>
<th>31 December 2018</th>
<th>31 December 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>7,136</td>
<td>7,454</td>
</tr>
</tbody>
</table>

The SCR spread risk on balance slightly decreased in 2018. On the one hand SCR spread risk increased due to a larger fixed income portfolio. On the other hand SCR spread risk decreased due to the shortening duration of the credit portfolio.

Solvency II sensitivities - spread risk

<table>
<thead>
<tr>
<th>Effect on:</th>
<th>Available capital</th>
<th>Required capital</th>
<th>Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spread +75bps/VA +20/21bps</td>
<td>-1</td>
<td>-2</td>
<td>-1</td>
</tr>
</tbody>
</table>

The sensitivity to spread risk is measured as the impact of an increase of spread on loans and corporate bonds of 75 bps. The volatility adjustment is based on a reference portfolio. An increase of 75 bps of the spreads on loans and corporate bonds within the reference portfolio leads to an increase of the VA with 20 bps in 2018 (2017: 21 bps).
Composition of fixed income portfolio
Spread risk is managed on a portfolio basis within limits and risk budgets established by the relevant risk committees. Where relevant, credit ratings provided by the external rating agencies are used to determine risk budgets and monitor limits. A limited number of fixed-income investments do not have an external rating. These investments are generally assigned an internal rating. Internal ratings are based on methodologies and rating classifications similar to those used by external agencies. The following tables provide a detailed breakdown of the fixed-income exposure by (i) rating class and (ii) sector. Assets in scope of spread risk are, by definition, not in scope of counterparty default risk.

The total exposure of assets in scope of spread risk is €204 million (2017: €188 million). The increase of the portfolio is mainly due to transactions. These transactions leads to changes in the portfolio decomposition:
- The amount of non-core government bonds and financials increased and the amount of corporates decreased;
- The amount of AAA rated bonds decreased and the amount of lower rated bonds increased.

Composition fixed income portfolio

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Government core</td>
<td>7%</td>
<td>7%</td>
</tr>
<tr>
<td>Government non core</td>
<td>24%</td>
<td>18%</td>
</tr>
<tr>
<td>Financials</td>
<td>36%</td>
<td>33%</td>
</tr>
<tr>
<td>Corporates</td>
<td>30%</td>
<td>39%</td>
</tr>
<tr>
<td>Structured instruments</td>
<td>0%</td>
<td>2%</td>
</tr>
<tr>
<td>Deposits</td>
<td>3%</td>
<td>1%</td>
</tr>
<tr>
<td>Loans</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Preference shares</td>
<td>0%</td>
<td>0%</td>
</tr>
</tbody>
</table>

Composition fixed income by sector 2018

Composition fixed income by sector 2017

C.2.6 Market risk concentrations
Concentrations of market risk constitute an additional risk to an insurer. Concentration risk is the concentration of exposures to the same counterparty. Other possible concentrations (region, country, etc.) are not in scope. The capital requirement for concentration risk is determined in three steps:
1. determine the exposure above threshold. The threshold depends on the credit quality of the counterparty;
2. calculation of the capital requirement for each counterparty, based on a specified factor depending on the credit quality;
3. aggregation of individual capital requirements for the various counterparties.

According to the spread risk module, bonds and loans guaranteed by a certain government or international organization are not in scope of concentration risk. Bank deposits can be excluded from concentration risk if they fulfil certain conditions.
In order to avoid concentrations in a single obligor, a.s.r. applies a limit on maximum exposure for (i) issuers with a single A rating and higher and (ii) for issuers with a BBB rating on group level. The limits apply to the total investment portfolio, where government bonds are not included, which is consistent with Solvency II. Beside the limits on single obligors, a.s.r. applies also limits on the total level of the required capital for market risk concentrations for ASR Ziektekosten Basis.

Due to a well diversified investment portfolio, no material market risk concentrations occur.

C.3 Counterparty default risk

Counterparty default risk reflects possible losses due to unexpected default or deterioration in the credit standing of counterparties and debtors. Counterparty default risk affects several types of assets:

- Mortgages;
- Savings-linked mortgage loans;
- Derivatives;
- Reinsurance;
- Receivables;
- Cash and deposits.

Assets that are in scope of spread risk are, by definition, not in scope of counterparty default risk and vice versa. The Solvency II regime makes a distinction between two types of exposures:

- Type 1: These counterparties generally have a rating (reinsurance, derivatives, current account balances, deposits with ceding companies and issued guarantee (letter of credit). The exposures are not diversified.
- Type 2: These counterparties are normally unrated (receivables from intermediaries and policyholders, mortgages with private individuals or SMEs). The exposures are generally diversified.

The total capital requirement for counterparty risk is an aggregation of the capital requirement for type 1 exposure and the capital requirement for type 2 exposure by taking 75% correlation.

C.3.1 Mortgages

ASR Basis Ziektekostenverzekeringen N.V. has no mortgages on the balance sheet.

C.3.2 Savings-linked mortgage loans

ASR Basis Ziektekostenverzekeringen N.V. has no saving loans on the balance sheet.

C.3.3 Derivatives

ASR Basis Ziektekostenverzekeringen N.V. has no material derivatives on the balance sheet.

C.3.4 Reinsurance

ASR Basis Ziektekostenverzekeringen N.V. has no reinsurance contracts on the balance sheet.
C.3.5 Receivables

<table>
<thead>
<tr>
<th>Composition receivables</th>
<th>31 December 2018</th>
<th>31 December 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policyholders</td>
<td>11,927</td>
<td>14,853</td>
</tr>
<tr>
<td>Intermediaries</td>
<td>1,629</td>
<td>2,917</td>
</tr>
<tr>
<td>Reinsurance operations</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Health insurance fund</td>
<td>102,174</td>
<td>98,605</td>
</tr>
<tr>
<td>Other</td>
<td>-3,119</td>
<td>17,697</td>
</tr>
<tr>
<td>Total</td>
<td>112,611</td>
<td>134,072</td>
</tr>
</tbody>
</table>

C.3.6 Cash and cash equivalents

The current accounts amounted € 11,967 thousand in 2018 (2017: € 26,057 thousand).

<table>
<thead>
<tr>
<th>Composition reinsurance counterparties by rating</th>
<th>31 December 2018</th>
<th>31 December 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAA</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>AA</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>A</td>
<td>100%</td>
<td>33%</td>
</tr>
<tr>
<td>Lower than A</td>
<td>0%</td>
<td>67%</td>
</tr>
</tbody>
</table>

C.4 Liquidity risk

Liquidity risk is the risk that ASR Basis Ziektekostenverzekeringen N.V. is not able to meet its financial obligations to policyholders and other creditors when they become due and payable, at a reasonable cost and in a timely manner. Liquidity risk is not quantified in the Solvency Capital Requirement of ASR Basis Ziektekostenverzekeringen N.V. and is therefore separately discussed here.

ASR Basis Ziektekostenverzekeringen N.V. recognizes different levels of liquidity management. Short-term liquidity, or daily cash management, covers the day-to-day cash requirements under normal business conditions and targets funding liquidity risk. Long-term liquidity management considers business conditions in which market liquidity risk materialises. Stress liquidity management looks at the ability to respond to a potential crisis situation as a result of a market event and an ASR Basis Ziektekostenverzekeringen N.V.-specific event. Unexpected cash outflows could occur as result of lapses in the insurance portfolio. ASR Basis Ziektekostenverzekeringen N.V. monitors its liquidity risk scenarios via different risk reporting and monitoring processes including daily cash management reports, cash flow forecasts and stress scenario liquidity reports.

ASR Basis Ziektekostenverzekeringen N.V.'s liquidity management principle consists of three components. First, a well-diversified funding base is necessary in order to provide liquidity for cash management purposes. A portion of assets must be invested in unencumbered marketable securities that can be used for collateralized borrowing or asset sales. Second, the strategic asset allocation should reflect the expected and contingent liquidity needs of liabilities. Finally, an adequate and up-to-date contingency liquidity plan is in place to enable management to act effectively and efficiently in times of crisis.

In managing the liquidity risk from financial liabilities, ASR Basis Ziektekostenverzekeringen N.V. holds liquid assets comprising cash and cash equivalents and investment grade securities for which there is an active and liquid market. These assets can be readily sold to meet liquidity requirements. As at 31 December 2018, ASR Basis Ziektekostenverzekeringen N.V. had cash (€ 11,967 thousand), liquid government bonds (€ 61,621) and other bonds and shares. Furthermore a.s.r has access to multiple committed cash facilities in order to meet its liquidity needs in times of stress.

The following table shows the contractual cash flows of liabilities (excluding insurance contracts on behalf of policyholders) broken down in four categories. For liabilities arising from insurance contracts, expected lapses and mortality risk are taken into account. Profit-sharing cash flow of insurance contracts is not taken into account, nor are equities, property and swaptions.

In 2018 the liquidity risk table has been updated for better understanding of the future cash flows. Additional time buckets were added to increase granularity. The comparative figures have been adjusted accordingly.
## Contractual cashflows

<table>
<thead>
<tr>
<th></th>
<th>Payable on demand</th>
<th>&lt; 1 years</th>
<th>1-5 years</th>
<th>5-10 years</th>
<th>&gt; 10 years</th>
<th>Carrying value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>31 December 2018</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Financial Liabilities¹</td>
<td>2,297</td>
<td>478</td>
<td>-</td>
<td>-</td>
<td>10,000</td>
<td>12,775</td>
</tr>
<tr>
<td>Derivatives</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Insurance Liabilities</td>
<td>-</td>
<td>77,781</td>
<td>106,391</td>
<td>12</td>
<td>-</td>
<td>211,739</td>
</tr>
<tr>
<td>Future interest payments</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>2,297</td>
<td>78,260</td>
<td>106,391</td>
<td>12</td>
<td>10,000</td>
<td>224,535</td>
</tr>
<tr>
<td><strong>31 December 2017</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Financial Liabilities¹</td>
<td>3,754</td>
<td>451</td>
<td>-</td>
<td>-</td>
<td>10,000</td>
<td>14,205</td>
</tr>
<tr>
<td>Derivatives</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Insurance Liabilities</td>
<td>-</td>
<td>73,789</td>
<td>114,773</td>
<td>-18</td>
<td>-</td>
<td>225,921</td>
</tr>
<tr>
<td>Future interest payments</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>3,754</td>
<td>74,241</td>
<td>114,773</td>
<td>-18</td>
<td>10,000</td>
<td>240,126</td>
</tr>
</tbody>
</table>

• (1) subordinated liabilities based on maturity date;
• Financial liabilities payable on demand include the liability recognised for cash collateral received under ISDAs, concluded with counterparties;
• The related cash collateral received is recognised as cash and cash equivalents, and not part of the liquidity risk exposure table. See Chapter C.3.6 Cash and cash equivalents;
• Expected cash flows based on assumptions made at year end 2018;
• Financial liabilities is excluding interest on perpetual loan of €10 mln 4.5% interest. Excluding interest on cash collateral received.

### EPIFP

#### EPIFP

<table>
<thead>
<tr>
<th></th>
<th>31 December 2018</th>
<th>31 December 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPIFP</td>
<td>4,119</td>
<td>-</td>
</tr>
</tbody>
</table>

### C.5 Operational risk

Operational risk is the risk of losses resulting from inadequate or failing internal processes, persons and systems, or from external events (including legal risk).

The main areas where operational risks are incurred are operations, IT, outsourcing, integrity and legal issues.

### Operational risk - required capital

<table>
<thead>
<tr>
<th></th>
<th>31 December 2018</th>
<th>31 December 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCR operational risk - required capital</td>
<td>18,514</td>
<td>17,377</td>
</tr>
</tbody>
</table>

The SCR for operational risk amounts to €18,514 thousand at the end of 2018 and is determined with the standard formula under Solvency II. The operational risk is based on the basic solvency capital requirement, the volumes of premiums and technical provisions, and the amount of expenses.

### C.6 Other material risks

As part of the regular ORSA process, the overall risk profile and associated solvency capital needs are assessed against a.s.r.’s actual solvency capital position. The most important risks to which a.s.r. is exposed, including risks that are not incorporated into the standard formula, are identified through a combined top-down (strategic risk assessment) and bottom-up (control risk self-assessments) approach.
After assessment of the effectiveness of the mitigating measures, the risks with the highest ‘Level of Concern’ or ‘LoC’ are translated to the a.s.r. risk priorities and relevant risk scenarios for the ORSA. The following risks, outside the scope of the standard formula, are recognized by a.s.r. as being potentially material:

- Inflation risk;
- Reputation risk;
- Liquidity risk;
- Contagion risk;
- Legal environment risk;
- Model risk;
- Risks arising from non-insurance activities (non-OTSOs);
- Strategic risk;
- Emerging risk.

As part of the appropriateness assessment of the standard formula mitigating measures regarding these risks are identified and evaluated.

C.7 Any other information

C.7.1 Description of off-balance sheet positions

Not applicable for ASR Basis Ziektekostenverzekeringen N.V.

C.7.2 Reinsurance policy and risk budgeting

C.7.2.1 Reinsurance policy

ASR Basis Ziektekostenverzekeringen N.V. does not reinsurance any specific underwriting risk at this moment.

C.7.2.2 Risk budgeting

Group Risk Management, Compliance, and Legal Affairs participate in the Product Approval & Review Process Board (PARP Board). All these departments evaluate whether risks in newly developed products are sufficiently addressed. New products need to be developed in a way that they are cost efficient, reliable, useful and secure. New products must also be strategically aligned with a.s.r.’s mission to be a solid and trustworthy insurer. In addition, the risks of existing products are evaluated, as requested by the PARP, as a result of product reviews.

C.7.3 Monitoring of new and existing products

Group Risk Management, Compliance, and Legal Affairs participate in the Product Approval & Review Process Board (PARP Board). All these departments evaluate whether risks in newly developed products are sufficiently addressed. New products need to be developed in a way that they are cost efficient, reliable, useful and secure. New products must also be strategically aligned with a.s.r.’s mission to be a solid and trustworthy insurer. In addition, the risks of existing products are evaluated, as requested by the PARP, as a result of product reviews.

C.7.4 Prudent Person Principle

a.s.r. complies with the prudent person principles as set out in Directive 2009/138/EC/article 132: Prudent person principle. The prudent person principle ensures that assets are managed on behalf of its subsidiaries, policyholders or other stakeholders in a prudent manner, and covers aspects that relate to market, credit, liquidity and operational risk. a.s.r. has mandated asr vermogensbeheer NV as their asset manager.

a.s.r. ensures that assets of policyholders or other stakeholders are managed in a prudent manner. a.s.r. complies with the “Prudent Person Principle” by investing only in assets and instruments which a.s.r. can adequately assess, measure, monitor, control, maintain and report the risks. All assets will be assessed against solvency criteria according to article 45 (1a).

Derivatives are only used when these contribute to a lower risk or when it can be used to manage/hedge the portfolio more efficient. Mortgages, real estate and illiquid assets, which are not traded on regulated financial markets, are limited to a prudent level.

Governance of Investments

Within the Three Lines-of-Defence model, investments are managed in the first line by asr vermogensbeheer NV, reporting to the CFO of a.s.r.

asr vermogensbeheer NV manages its investments within the boundaries of a.s.r.’s Risk Appetite Framework, Strategic Asset Allocation and its Market-Risk Budget. The Market-Risk Budget is calculated on a monthly basis by Group Balance Sheet Management (GBSM), taking into account the Risk Appetite Framework. Group Risk Management, acting as the second line of defence, is responsible for the review. Internal Audit acts as the third-line of defence.

a.s.r. has established a structure of risk committees with the objective to monitor the risk profile for a.s.r. group, its legal entities and its business lines in order to ensure that it remains within the risk appetite and the underlying risk tolerances and risk limits. When triggers are hit or likely to be hit, risk committees make decisions regarding measures to be taken, being risk-mitigating measures or measures regarding governance, such as the frequency of their meetings.

All investments related activities are performed according to mandates as set by a.s.r., clients or policyholders. Mandates for investments for own account, clients and for account of policyholders are set out in internal guidelines, in order to ensure that prudent person principles are satisfied. This should always be in line with internal policies and internal constraints (such as a.s.r.’s ESG policy) and external constraints (such as regulatory limits).
This chapter contains information regarding the valuation of the balance sheet items. For each material asset class, the bases, methods and main assumptions used for valuation for solvency purposes are described. Separately for each material class of assets a quantitative and qualitative explanation of any material difference between the valuation for solvency purposes and valuation in the financial statements. When accounting principles are equal or when line items are not material, some line items are clustered together.

Valuation of assets is based on fair value measurement as described below. Each material asset class is described in paragraph D.1. Valuation of technical provisions is calculated as the sum of the best estimate and the risk margin. This is described in paragraph D.2. Other liabilities are described in paragraph D.3.

Information for each material line item is based on the balance sheet below. For each line item is described:
- Methods and assumptions for valuation;
- Difference between solvency valuation and valuation in the financial statements.

The numbering of the line items refers to the comments below.

Based on the differences in this template a reconciliation is made between IFRS equity and Solvency equity for 2018.

### Reconciliation IFRS balance sheet and Solvency II balance sheet

<table>
<thead>
<tr>
<th>Balance sheet</th>
<th>31 December 2018 IFRS</th>
<th>Revaluation</th>
<th>31 December 2018 Solvency II</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Deferred acquisition costs</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>2. Intangible assets</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>3. Deferred tax assets</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>4. Property, plant, and equipment held for own use</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>5. Investments - Property (other than for own use)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>6. Investments - Equity</td>
<td>5,841</td>
<td>-</td>
<td>5,841</td>
</tr>
<tr>
<td>7. Investments - Bonds</td>
<td>198,185</td>
<td>-</td>
<td>198,185</td>
</tr>
<tr>
<td>8. Investments - Derivatives</td>
<td>6</td>
<td>-</td>
<td>6</td>
</tr>
<tr>
<td>9. Unit-linked investments</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>10. Loans and mortgages</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>11. Reinsurance</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>12. Cash and cash equivalents</td>
<td>11,967</td>
<td>-</td>
<td>11,967</td>
</tr>
<tr>
<td>13. Any other assets, not elsewhere shown</td>
<td>120,986</td>
<td>-4,427</td>
<td>116,559</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>336,985</strong></td>
<td><strong>-4,427</strong></td>
<td><strong>332,558</strong></td>
</tr>
<tr>
<td>14. Technical provisions (best estimates)</td>
<td>211,739</td>
<td>-27,480</td>
<td>184,259</td>
</tr>
<tr>
<td>15. Technical provisions (risk margin)</td>
<td>-</td>
<td>7,776</td>
<td>7,776</td>
</tr>
<tr>
<td>16. Unit-linked best estimate</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>17. Unit-linked risk margin</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>18. Pension benefit obligations</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>19. Deferred tax liabilities</td>
<td>264</td>
<td>3,723</td>
<td>3,987</td>
</tr>
<tr>
<td>20. Subordinated liabilities</td>
<td>10,000</td>
<td>388</td>
<td>10,388</td>
</tr>
<tr>
<td>21. Other liabilities</td>
<td>7,735</td>
<td>-</td>
<td>7,735</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td><strong>229,738</strong></td>
<td><strong>-15,593</strong></td>
<td><strong>214,145</strong></td>
</tr>
<tr>
<td><strong>Excess of assets over liabilities</strong></td>
<td><strong>107,247</strong></td>
<td><strong>11,166</strong></td>
<td><strong>118,413</strong></td>
</tr>
</tbody>
</table>
This chapter contains also the reconciliation between the excess of assets over liabilities to EOF.

### Reconciliation excess of assets over liabilities to Eligible Own Funds

<table>
<thead>
<tr>
<th>Gross of tax 31 December 2018</th>
<th>107,247</th>
</tr>
</thead>
<tbody>
<tr>
<td>IFRS equity</td>
<td></td>
</tr>
<tr>
<td><strong>Revaluation assets</strong></td>
<td></td>
</tr>
<tr>
<td>i. Intangible assets</td>
<td>-</td>
</tr>
<tr>
<td>ii. Loans and mortgages</td>
<td>-</td>
</tr>
<tr>
<td>iii. Reinsurance</td>
<td>-</td>
</tr>
<tr>
<td>iv. Cash and cash equivalents</td>
<td>-</td>
</tr>
<tr>
<td>v. Any other assets, not elsewhere shown</td>
<td>-4,427</td>
</tr>
<tr>
<td><strong>Revaluation liabilities</strong></td>
<td></td>
</tr>
<tr>
<td>i. Technical provisions (best estimates)</td>
<td>27,480</td>
</tr>
<tr>
<td>ii. Technical provisions (risk margin)</td>
<td>-7,776</td>
</tr>
<tr>
<td>iii. Unit-linked best estimate</td>
<td>-</td>
</tr>
<tr>
<td>iv. Unit-linked risk margin</td>
<td>-</td>
</tr>
<tr>
<td>v. Subordinated liabilities</td>
<td>-388</td>
</tr>
<tr>
<td>vi. Other liabilities</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total gross revaluations</strong></td>
<td>14,889</td>
</tr>
<tr>
<td><strong>Tax percentage</strong></td>
<td>25%</td>
</tr>
<tr>
<td><strong>Total net revaluations</strong></td>
<td>11,166</td>
</tr>
<tr>
<td><strong>Other Revaluations</strong></td>
<td></td>
</tr>
<tr>
<td>i. Goodwill</td>
<td>-</td>
</tr>
<tr>
<td><strong>Solvency II equity</strong></td>
<td>118,413</td>
</tr>
<tr>
<td><strong>Own fund items</strong></td>
<td></td>
</tr>
<tr>
<td>i. Subordinated liabilities</td>
<td>10,388</td>
</tr>
<tr>
<td>ii. Foreseeable dividends</td>
<td>-</td>
</tr>
<tr>
<td><strong>Eligible Own Funds Solvency II</strong></td>
<td>128,801</td>
</tr>
</tbody>
</table>

### D.1 Assets

Valuation of most financial assets is based on fair value. In the paragraph below, this valuation methodology is described. For different line items will be referred to this method. In this paragraph line items 1 – 15 from the simplified balance sheet above are described.

#### D.1.1 Fair value measurement

In accordance with the Delegated Regulation, Solvency II figures are based on fair value. In line with the valuation methodology described in article 75 and further of the Solvency II directive and articles 9 and 10, the following three hierarchical levels are used to determine the fair value of financial instruments and non-financial instruments when accounting for assets and liabilities at fair value:

1. **Level 1: Fair value based on quoted prices in an active market**
   - Level 1 includes assets and liabilities whose value is determined by quoted (unadjusted) prices in the primary active market for identical assets or liabilities.
   - A financial instrument is quoted in an active market if:
     - quoted prices are readily and regularly available (from an exchange, dealer, broker, sector organisation, third party pricing service, or a regulatory body); and
     - these prices represent actual and regularly occurring transactions on an arm’s length basis.

2. **Level 2: Fair value based on observable market data**
   - Determining fair value on the basis of Level 2 involves the use of valuation techniques that use inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is derived from prices of identical or
similar assets and liabilities). These observable inputs are obtained from a broker or third party pricing service and include:

- Quoted prices in active markets for similar (not identical) assets or liabilities;
- Quoted prices for identical or similar assets or liabilities in inactive markets;
- Input variables other than quoted prices observable for the asset or liability. These include interest rates and yield curves observable at commonly quoted intervals, volatility, loss ratio, credit risks and default percentages.

**Level 3: Fair value not based on observable market data**

The fair value of the level 3 assets and liabilities are determined in whole or in part using a valuation technique based on assumptions that are not supported by prices from observable current market transactions in the same instrument and for which any significant inputs are not based on available observable market data. The financial assets and liabilities in this category are assessed individually.

Valuation techniques are used to the extent that observable inputs are not available. The basic principle of fair value measurement is still to determine a fair, arm’s length price. Unobservable inputs therefore reflect management’s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk). These inputs are generally based on the available observable data (adjusted for factors that contribute towards the value of the asset) and own source information.

**D.1.2 Assets per asset category**

The balance sheet reports specify different asset categories. In this section, we describe the valuation of each material asset category. The figures correspond to the extended balance sheet which has been reported as QRT S 2.01.

1. **Deferred acquisition costs**
   Not applicable for ASR NL Basis Ziektekostenverzekeringen N.V.

2. **Intangible assets**
   The intangible assets related to goodwill and other intangible assets are not recognized in the Solvency II framework and are set to nil.

3. **Deferred tax assets**
   The basis for the DTA / DTL position in the IFRS balance sheet is temporary differences between fiscal and commercial valuation. This DTA / DTL position is the base for this line item on the Solvency II balance sheet, adjusted for Solvency II revaluations, such as revaluation of technical provisions.

In accordance with the Delegated Regulation the DTA / DTL position is netted in the balance sheet. The balance sheet of a.s.r. contains a DTL.

The deferred tax effects involve a correction related to the fact that (most of) the revaluations as described in this chapter are gross of tax. The tax effect is calculated as 20.5%.

4. **Property plant, and equipment held for own use**
   Not applicable for ASR Basis Ziektekostenverzekeringen N.V.

5. **Investments - Property (other than for own use)**
   Not applicable for ASR Basis Ziektekostenverzekeringen N.V.

6. **Investments – Equity**

   Valuation of listed equities is based on the level 1 method of the fair value hierarchy. Unlisted fixed-interest preference shares are valued based on the level 2 method of the fair value hierarchy. The valuation techniques for financial instruments start from present value calculations; derivatives are valued based on forward-pricing and swap models. The observable market data contains yield curves based on company ratings and characteristics of unlisted fixed-interest preference shares. The main non-observable market input for private equity investments is the net asset value of the investment as published by the private equity company (or partner).

   Valuation of private equity investments is based on the level 3 method of the fair value hierarchy. The main non-observable market input for private equity investments is the net asset value of the investment as published by the private equity company (or partner).

7. **Investments – Bonds**

   The valuation of these assets is consistent with the IFRS fair value hierarchy as described in paragraph D.1.1.

8. **Investments – Derivatives**

   The valuation of these assets is consistent with the fair value hierarchy as described in paragraph D.1.1. The valuation of listed derivatives is based on the level 1 method of the fair value hierarchy. The valuation of unlisted interest rate contracts is based on the level 2 method of the fair value hierarchy. The valuation techniques for financial instruments start from present value calculations; derivatives are valued based on forward-pricing and swap models. The observable market data contains yield curves based on company ratings and characteristics of unlisted fixed-interest preference shares.

9. **Unit-linked investments**
   Not applicable for ASR Basis Ziektekostenverzekeringen N.V.

10. **Loans and mortgages**
    Not applicable for ASR Basis Ziektekostenverzekeringen N.V.
11. Reinsurance recoverables
Not applicable for ASR Basis Ziektekostenverzekeringen N.V.

12. Cash and cash equivalents
The valuation of cash and cash equivalents is based on the level 1 method of the fair value hierarchy. Cash and cash equivalents include cash in hand, deposits held at call with banks, cash collateral and other short-term highly liquid investments with original maturities of three months or less.

13. Any other assets, not elsewhere shown
The valuation of these assets is based on the IFRS fair value hierarchy as described in paragraph Section D.1.1. Other assets include different investments and interest income, property developments, tax assets and accrued assets.

Discontinued operations
Discontinued operations are recognized on the IFRS Balance sheet as a single line item. These assets are recognized on a line by line basis in the Solvency II balance sheet.

D.2 Technical provisions
D.2.1 Introduction
In this section, the policies regarding methodology and assumptions for the technical provisions are described. These liabilities arise from insurance contracts issued by ASR Basis Ziektekostenverzekeringen N.V.

D.2.2 Technical provisions methods
D.2.2.1 Medical expense insurance
What follows is a description of the policies, methods and principal assumptions that were decisive in determining the value of the technical provisions and the risk margin.

Composition of homogeneous risk group for ASR Basis Ziektekostenverzekeringen N.V.
A homogeneous risk group (HRG) encompasses a collection of policies with similar risk characteristics as stipulated by Solvency II, which are generally recorded separately. For ASR Basis Ziektekostenverzekeringen N.V. the coverage is determined by the national government. Therefore, all the coverages are the same for all labels and distribution channels. Also, a basic health insurance is a mandatory insurance for all inhabitants in The Netherlands. For these two reasons one HRG is defined.

Contract boundary
The government decides on the basic health insurance package every year and this package is mandatory for all inhabitants of The Netherlands. The composition of this package may be different from year to year. In addition, the contract boundary of an insurance contract is just one calendar year which is laid down in law. Insured persons are free to accept or reject a new offer from their health insurer after one year. The composition of the portfolio changes mainly because of insured persons switching health insurers. Claims incurred during the period of cover continue to be insurance liabilities for the covering health insurer. The insurance portfolio and hence the risk profile stays stable during one year, because of the breakdown by claim year.

Risk equalization model
The Dutch Health Insurance is laid down in law (Zw7) and is supplemented by a risk equalization model which is performed by the National Health Care Institute (ZINL) for the basis insurance contract.

The risk equalization model compensates health insurers for differences in the composition of their insured population creating a level playing field. All health insurance companies receive an equalization premium from ZINL on an annual basis, of which the amount depends on the insured population. The insurance companies receive the equalization premiums for every underwriting year over a period of two years according to a pre-defined payment schedule. The equalization premium is estimated beforehand by ZINL and is corrected afterwards based on the realized insured population. The equalization premium is determined definitively after 4.5 years. The estimated equalization premium beforehand is called “ex ante” and the difference between ex ante and the corrected realized equalization premium is called “ex post”.

The equalization premium should cover 50% of all health expenses nationally. The second 50% should be covered by a commercial premium per person above eighteen, calculated by each health insurer independently.

D.2.2.2 Bases and methods
Best estimate claim provision ASR Basis Ziektekostenverzekeringen N.V.
The inflation method is used for the first months of the new year because little is known about the use of health care and its declaration pattern of the new year. The inflation rate is based on the existing contracts from the previous year which are under negotiation for new year and market rates for health care consumption.

The outstanding claims provisions for basic health insurance are determined by the health care purchasing method. This method that has been applied for calculating the best estimate claims provisions for Specialist Medical Care (MSZ) and Mental Health Care (GGZ) is based on contractual tariff agreements per claim year with individual health institution like hospitals and mental health care institutions. MSZ and GGZ determined more than 65% of the total best estimate provisions. In almost all the contractual agreements a maximum of

---

7 Zvw. Zorgverzekeringswet
The cash flow pattern of the future claim provision is based on paid claims in a chain ladder model. The assumptions are:

A. Claims received in past months are predictive for the future payment pattern of claims.
B. The payment patterns are constant / equal divided for the coming months to year end.
C. The payment pattern for the future claims is equal to the payment pattern of the current (already) paid claims.

The same yield curve, which a.s.r. sets internally at group level and subsequently supplied to the supervised entity, is used as for the outstanding claims provisions.

**Claims handling costs ASR Basis Ziektekostenverzekeringen N.V.**

The cash flows for claims handling costs are proportional to the cash flows of the paid claims for the claim provisions. The percentage of claim handling costs is equal to the ratio ‘released claims handling costs at the end of year T-1 divided by paid claims including own risk at the end of year T-1 independent of claim years. This fixed percentage is applied to the outstanding claims provision for the current year in the reporting period (t) and for earlier years (t-1, t-2, …, t-n), and to the outstanding claims provision for future years in earlier years. The result is a provision for claims handling costs. The provision for claims handling costs is included in the best estimate for the outstanding claims and premium provisions. The remaining (other) costs are paid uniformly in a year.

**Risk margin methodology**

The insurance risks have been determined in accordance with the standard formula described in the Delegated Regulation. a.s.r. group applies the Cost of Capital method that is applicable to ASR Basis Ziektekostenverzekeringen N.V. and ASR Aanvullende Ziektekostenverzekeringen N.V. as well with a Cost of Capital rate of 6%.

Solvency II describes 4 methods to calculate the risk margin. a.s.r. group has chosen to use the alternative method 1. This method calculates the required future capitals by an approach per risk (sub) module. An approach can of course also be the full calculation of the risk module. The required capital uses the SCR for non-hedgeable risks type 2.

**Impact volatility adjustment**

ASR Basis Ziektekostenverzekeringen N.V. applies the volatility adjustment for discounting cash flows to determine the best estimate and in determining the Required Capitals for the SCR. In the next table the impact is shown of this volatility adjustment on the financial position and own funds of ASR Basis Ziektekostenverzekeringen N.V.
D.2.3 Level of uncertainty

This paragraph contains a description of group policy, which is applicable for the solo entity. a.s.r. distinguishes between two sources of uncertainty with regard to the level of the technical provisions. These sources are model risk and process risk. The uncertainty associated with these risks has been mitigated as described below.

Process risk

The process risk is mitigated using the Management in Control framework (MIC), which creates a reasonable degree of assurance as to the reliability of financial reports. Key controls have been identified and to a larger extent implemented for the calculation process. In addition, the effectiveness of the MIC framework is verified by an independent party and supplementary checks are performed where needed. As part of MIC or the additional checks, the four-eye principle has demonstrably been applied to the calculation of the technical provision.

Model risk

The second risk that a.s.r. has identified in relation to the technical provisions is model risk. Regular procedures have provided adequate certainty with regard to this risk. To illustrate, a model validation process mitigates the risk of material misstatements or that key facts have been omitted. In addition, FRM, in its role as the second line of defense, performs an independent internal review of the technical provisions as described in the previous phase.

D.2.4 Reinsurance and special purpose vehicles (SPVs)

Not applicable to ASR Basis Ziektekostenverzekeringen N.V.

D.2.5 Technical provisions

In this table a reconciliation is made between the Solvency II and the IFRS valuation of provisions. Solvency figures are part of the balance sheet S.02.01. The next paragraph describes a brief explanation of these differences.

D.2.6 Reconciliation between IFRS and Solvency II

Under Solvency II, the technical provisions are calculated using a different method compared to IFRS. In this section the reconciliation between IFRS and Solvency II is described per business line.

Similar to Non-life

The revaluation for Similar to Non-life (medical expense) is caused by:
- Ex post;
- Different assumptions and methods underlying the technical provisions.

D.3 Other liabilities

D.3.1 Valuation of other liabilities

In line with the valuation of assets, the accounting principles for other liabilities used in the Pillar III reports are generally also based on the IFRS as adopted by the EU. Any differences between the valuation methods for IFRS and Solvency II purposes are addressed in detail per liability category. In this paragraph line items 18-21 from the simplified balance-sheet above are described

18. Pension benefit obligations

Not applicable for ASR Basis Ziektekostenverzekeringen N.V.

On group level a.s.r. has in place a number of defined benefit plans for own staff. Current service costs for the OTSO's are included in operating expenses.
19. Deferred tax liabilities
See 3. Deferred tax assets.

20. Subordinated liabilities
In IFRS the perpetual hybrid loans are classified as equity as there is no requirement to settle the obligation in cash or another financial asset or to exchange financial assets or financial liabilities under conditions that are potentially unfavourable for ASR Basis Ziektekostenverzekeringen N.V.

According to IFRS, the perpetual hybrid loans are measured at amortized cost. For the purpose of Solvency II, they are both measured at fair value.

Directed by the regulator in Solvency reporting the perpetual hybrid loans are classified as subordinated liabilities.

21. Other liabilities
Other Liabilities contains different small line items:

Insurance and Intermediaries payables
The valuation of these liabilities follows the Solvency II fair value hierarchy as described in paragraph D.1.1. This category is subject to the same valuation as the asset category Cash and Cash equivalents.

Trade payables (non-insurance)
The valuation of these liabilities follows the Solvency II fair value hierarchy as described in paragraph D.1.1. This category is subject to the same valuation as the asset category receivables.

Any other liabilities not disclosed elsewhere
The valuation of these liabilities follows the Solvency II fair value hierarchy as described in paragraph D.1.1. This item consists primarily of tax payables.

Contingent liabilities
Contingent liabilities are defined as:
- A possible obligation depending on whether some uncertain future event occurs, or
- A present obligation but payment is not probable or the amount cannot be measured reliably.

Contingent liabilities are recognized on the IFRS balance sheet if there is a probability of >50% that the contingent liability leads to an "outflow of resources". These liabilities are also recognized on the Solvency II balance sheet.

Solvency II prescribes that all contingent liabilities be recognized on the Solvency II balance sheet. This covers cases where the amount cannot be measured reliably or when the probability is <50%. For these cases, a regular process is in place to determine whether contingent liabilities should be recognized on the Solvency II balance sheet.

The ASR Basis Ziektekostenverzekeringen N.V. Solvency II capital ratio does not include contingent liabilities.

D.3.2 Reconciliation from Solvency II equity to EOF
The differences described in the above sections are the basis for the reconciliation of IFRS equity to equity Solvency II. To reconcile from Solvency II Equity to EOF, the following movements are taken into consideration:

Subordinated liabilities
In accordance with the Delegated Regulation the subordinated liabilities are part of the EOF. Further information of this liabilities is described in section E.

Foreseeable dividends and distributions
Not applicable for ASR Basis Ziektekostenverzekeringen N.V.

Deductions for participations in financial and credit institutions
Not applicable for ASR Basis Ziektekostenverzekeringen N.V.

Tier 3 Limitation
In accordance with the Delegated Regulation EOF is divided in tiering components. There are boundary conditions related to the size of these components. Excess of this limits results in capping of EOF. For ASR Basis Ziektekostenverzekeringen N.V. capping does not apply per Q4 2017.

D.4 Alternative methods for valuation
ASR Basis Ziektekostenverzekeringen N.V. does not apply alternative methods for valuation.

D.5 Any other information
Not applicable for ASR Basis Ziektekostenverzekeringen N.V.
The solvency ratio stood at 140% as at 31 December 2018 based on the standard formula as a result of €128,801 thousand EOF and €92,071 thousand SCR.
An extensive explanation of the reconciliation from IFRS equity to Solvency II eligible own funds was presented in section D.3.2.

## E.1 Own funds

### E.1.1 Capital management objectives

**Management**

Overall capital management is administered at group level. a.s.r. currently plans to consider investing capital above the Solvency II ratio (calculated based on the standard formula) of 160% (management threshold level) with the objective of creating value for its shareholders. If and when a.s.r. operates at a level considerably above the management threshold level and it believes that it cannot invest this capital in value-creating opportunities for a prolonged period of time, it may decide to return (part of this) capital to shareholders. If a.s.r. chooses to return capital, it plans to do so in a form that is efficient for shareholders at that time. a.s.r. actively manages its in-force business, which is expected to result in free capital generation over time. Additionally, business improvement and balance sheet restructuring should improve the capital generation capacity while advancing the risk profile of the company. The legal entities are individually capitalised and excess capital over management’s targets for the legal entities is intended to be up-streamed to the holding company as far as is needed for amongst others covering external dividend, coupon payments on hybrids/senior financing instruments and holding costs and in so far the local regulations and the internal risk appetite statement allow.

**Objectives**

The group is committed to maintain a strong capital position in order to be a robust and sustainable insurer for its policyholders and other stakeholders. The objective is to maintain a solvency ratio well above the minimum levels as defined in the risk appetite statements and above the relevant management threshold levels. Sensitivities are periodically performed for principal risks and annual stress tests are performed to test a.s.r.’s robustness to withstand moderate to severe scenarios. An additional objective is to achieve a combination of a capital position and a risk profile that is at least in line with a “single A” rating by Standard & Poor’s.

The SCR is reported on a quarterly basis and proxies are made on both a monthly and weekly basis. The internal minimum solvency ratio for a.s.r. as formulated in the risk appetite statement is 110%. The lower limit solvency target is 130%. ASR Basis Ziektekostenverzekeringen N.V. does not have a management target. The solvency ratio stood at 140% at 31 December 2018, which was above the internal requirement of 110%.

In accordance with a.s.r.’s dividend policy, the liquidity of the underlying entities is not taken into account for the liquidity position of the group. However, the capital is recognized in the capital position of the group, since a.s.r. has the ability to realize the capital of this OTSO, for example by selling the entity. Specifically regarding Basis Ziektekostenverzekeringen N.V. in 2018, no dividend or capital withdrawals have taken place taken place in line with the capital policy.

In determining the SCR ratio (140%), a € 10 million subordinated loan from ASR Nederland N.V. issued in 2004, has been taken into account in the EOF in the annual report and the SFCR report. This is above the lower limit solvency target of 130%. Recently it has been established that the subordinated loan does not meet all conditions under Solvency I which is required for grandfathering under Solvency II.

Therefore, in the beginning of 2019, in consultation with the supervisor the subordinated loan contract has been amended to aligned with the Solvency II directives. As there has been no change in the funding related to the subordinated loan, ASR Basis Ziektekostenverzekeringen N.V. continues to present the SCR ratio taking into account the subordinated loan at the end of 2018 in the public reported SFCR. In the formal QRT report to the supervisor,
the loan is not included in EOF. For this reason the SCR ratio in the QRT appendix as at 31 December 2018 is 129%.

(SCR ratio 2017 is 138% including the subordinated loan and 127% excluding the subordinated loan)

The table below shows how the eligible own funds of a.s.r. relate to the different capital targets.

**Market value own funds under SCR**

![Graph showing market value own funds under SCR]

**E.1.2 Tiering own funds**

The table below details the capital position of ASR Basis Ziektekostenverzekeringen N.V. as at the dates indicated. With respect to the capital position, Solvency II requires the insurers to categorize own funds into the following three tiers with differing qualifications as eligible available regulatory capital:

- Tier 1 capital consists of Ordinary Share Capital and Reconciliation reserve.
- Tier 2 capital consists of ancillary own funds and basic Tier 2. Ancillary own funds consist of items other than basic own funds which can be called up to absorb losses. Ancillary own fund items require the prior approval of the supervisory authority. ASR Basis Ziektekostenverzekeringen N.V. has no ancillary own fund items.
- Tier 3 consists of Deferred tax assets.

The rules impose limits on the amount of each tier that can be held to cover capital requirements with the aim of ensuring that the items will be available if needed to absorb any losses that might arise.

<table>
<thead>
<tr>
<th>Eligible Own Funds to meet the SCR</th>
<th>31 December 2018</th>
<th>31 December 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tier 1 capital - unrestricted</td>
<td>118,413</td>
<td>115,814</td>
</tr>
<tr>
<td>Tier 1 capital - restricted</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Tier 2 capital</td>
<td>10,388</td>
<td>10,391</td>
</tr>
<tr>
<td>Tier 3 capital</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eligible own funds to meet SCR</td>
<td>128,801</td>
<td>126,205</td>
</tr>
</tbody>
</table>

**E.1.3 Own funds versus MCR**

The MCR calculation is based on the standard formula.

<table>
<thead>
<tr>
<th>Eligible Own Funds to meet the MCR</th>
<th>31 December 2018</th>
<th>31 December 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tier 1 capital - unrestricted</td>
<td>118,413</td>
<td>115,814</td>
</tr>
<tr>
<td>Tier 1 capital - restricted</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Tier 2 capital</td>
<td>7,446</td>
<td>7,144</td>
</tr>
<tr>
<td>Tier 3 capital</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eligible own funds to meet MCR</td>
<td>125,859</td>
<td>122,958</td>
</tr>
</tbody>
</table>

According to Delegated Regulation article 248 to 251 the MCR (€ 37,231 thousand) of ASR Aanvullende Ziektekostenverzekeringen N.V. is calculated as a linear function of premiums, technical provisions and capital at risk.
E.1.4 Description of grandfathering

Grandfathering is not applicable for ASR Basis Ziektekostenverzekeringen N.V.

E.2 Solvency Capital Requirement

Capital requirement

The required capital stood at € 92,071 thousand per 31 December 2018. The required capital (before diversification) consists for € 7,228 thousand out of market risk and the insurance risk amounted to € 70,379 thousand as per 31 December 2018.

<table>
<thead>
<tr>
<th>Eligible Own Funds to meet the SCR</th>
<th>31 December 2018</th>
<th>31 December 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligible Own Funds Solvency II</td>
<td>128,801</td>
<td>126,205</td>
</tr>
<tr>
<td>Required capital</td>
<td>92,071</td>
<td>91,452</td>
</tr>
<tr>
<td>Solvency II ratio</td>
<td>140%</td>
<td>138%</td>
</tr>
</tbody>
</table>

Under Solvency II it is permitted to reduce the required capital with the mitigating tax effects resulting from a 1-in-200-year loss ("Shock loss"). There is a mitigating tax effect to the extent that the Shock loss (BSCR + Operational risk) is deductible for tax purposes and can be compensated with taxable profits. This positive tax effect can only be taken into account when sufficiently substantiated ('more likely than not'). a.s.r. included a beneficial effect on its solvency ratio(s) due to the application of the LAC DT. The LAC DT benefit for ASR Basis Ziektekostenverzekeringen N.V. is nil.

Relevant regulation and current guidance (Delegated Regulation, Level 3 guidelines, Dutch Central Bank Q&A’s and IAS12) is taken into account in the development of the LAC DT methodology.

E.3 Use of standard equity risk sub-module in calculation of Solvency Capital Requirement

The transitional measure for equity risk applies for shares in portfolio at 01-01-2016. The SCR equity shock is 22% at 01-01-2016, and linear increasing to (i) 39% + symmetric adjustment for type I shares and (ii) 49% + symmetric adjustment for type II shares.

The equity risk for ASR Basis Ziektekostenverzekeringen N.V. is very limited and is the result of an forced conversion. Therefore, the transitional measure for equity risk has no impact on the level of equity risk.

E.4 Differences between Standard Formula and internal models

a.s.r. solvency is governed by a standard formula, rather than the self-developed internal model. The Executive Board believes that this should enhance transparency and consistent interpretation.

E.5 Non-compliance with the Minimum Capital Requirement and non-compliance with the Solvency Capital Requirement

As ASR Basis Ziektekostenverzekeringen N.V. has not faced any form of non-compliance with the Minimum Capital Requirement or significant non-compliance with the Solvency Capital Requirement during the reporting period or at the reporting date, no further information is included here.
E.6 Any other information

E.6.1 Dividend and capital management actions

a.s.r. has formulated its dividend policy in line with its current strategy. a.s.r. and the underlying business entities intend to pay an annual dividend that creates sustainable long-term value for its shareholders. a.s.r. and the underlying business entities aim to operate at a solvency ratio, calculated according to the standard formula, above a management threshold level. “However, for ASR Basis Ziektekostenverzekeringen N.V. this management threshold is not applicable, this is in accordance with the capital policy that no dividend is paid from ASR Basis Ziektekostenverzekeringen N.V.